

ICoLA 2026

The 15th International Congress on
Lipid & Atherosclerosis

*“Bridge to Excellence,
Toward Cardiometabolic Health”*

PROGRAM BOOK



.....

September
10 (Thu)-12 (Sat), 2026

Conrad Seoul, Republic of Korea




▲ ABSTRACT BOOK DOWNLOAD

ICoLA | by KSoLA
International Congress on
Lipid and Atherosclerosis



KSoLA
The Korean Society of Lipid and Atherosclerosis

An Excellent Solution for the Integrated Management of Dyslipidemia and Hypertension



WELCOME MESSAGE

Dear Colleagues,

On behalf of the Organizing Committee, it is our great pleasure to welcome you to the 15th International Congress on Lipid and Atherosclerosis (ICoLA 2026), held from September 10 to 12, 2026, at Conrad Seoul, Republic of Korea.

This year's theme, "Bridge to Excellence, Toward Cardiometabolic Health," embodies our shared commitment to connecting scientific discovery with clinical practice and translating knowledge into better cardiometabolic health. It also reflects the essential bridges we continue to build—across disciplines, institutions, countries, and generations—to address the increasingly complex and interconnected challenges of dyslipidemia, atherosclerosis, and cardiovascular disease.

The scientific program of ICoLA 2026 has been designed to explore the full spectrum of lipid and cardiometabolic medicine, from molecular mechanisms and emerging therapeutic targets to prevention strategies, clinical implementation, and population health. Plenary and special lectures will offer perspectives on major advances and persistent challenges in cardiovascular prevention, while the main symposia will examine a broad range of timely topics, including inflammation and residual cardiovascular risk, lipoprotein(a), familial and severe dyslipidemia, obesity, fatty liver disease, chronic kidney disease, diabetes, vascular aging, novel lipid-lowering therapies, artificial intelligence, and environmental cardiovascular risk.

A particularly meaningful highlight of this year's congress is the official launch of the 2026 KSoLA Guidelines for the Management of Dyslipidemia, providing an important opportunity to consider how evolving evidence can be translated into more effective and practical patient care. Joint symposia with leading academic societies from Asia and Europe will further broaden the discussion by bringing together regional experience and international perspectives on the challenges shared across diverse healthcare settings.

The oral and moderated poster presentation sessions also form an essential part of the congress. We are especially pleased to provide early-career investigators with opportunities to present their work, engage with established experts, and contribute fresh ideas to our scientific community. We hope these exchanges will inspire new questions, collaborations, and discoveries extending well beyond the congress itself.

Now that we are gathered together in Seoul, we encourage you to take full advantage of the many opportunities for learning, discussion, and connection throughout the next three days. Your expertise, curiosity, and active participation are what give this congress its true meaning and vitality.

We sincerely thank all invited speakers, chairpersons, panelists, presenters, participants, partner societies, sponsors, and organizing members whose dedication has made ICoLA 2026 possible.

Once again, welcome to ICoLA 2026. We hope your time in Seoul will be scientifically rewarding, professionally enriching, and truly memorable.

Sincerely,



Sung Rae Kim

Sung Rae Kim
President, Board of Directors,
KSoLA




Sang-Hyun Kim


Sang-Hyun Kim
Chairman, Board of Directors,
KSoLA

Rosuzet Tab.
(Ezetimibe/Rosuvastatin)


- The world's first CV outcome publication on the combination of Rosuvastatin and Ezetimibe¹⁾
- The first prescription drug developed by a domestic company which took the No.1 position in Korea's outpatient prescriptions market²⁾
- Eighteen clinical studies on Korean patients with Rosuzet published in SCIE-indexed journals (As of Oct.2025)
- Global expansion through R&D and in-house manufacturing in Hanmi Pharmaceutical.



10 / 2.5 mg



10 / 5 mg



10 / 10 mg



10 / 20 mg

For personalized management of dyslipidemia in patients with multiple comorbidities, start with Rosuzet!

Active Form of Fenofibric Acid for Hypertriglyceridemia

Fenocid Cap.
(Fenofibric acid)


Omega-3 Fatty Acid-Based Therapy for Hypertriglyceridemia

HANMI **Omega** Soft Cap.
(Omega-3-acid ethyl esters 90)

Lipid-Lowering Therapy Compatible with Statins

Ezet Tab.
(Ezetimibe)

Amoprel Tab.
(Amlodipine / Losartan / Chlorthalidone)



(1.67/16.67/4.17mg)

- The world's first third-dose triple-combination antihypertensive medication
- Expected to provide stable blood pressure control through three complementary antihypertensive mechanisms^{3,4,5)}
- Demonstrated non-inferior blood pressure-lowering efficacy compared to Amlodipine 5 mg monotherapy⁶⁾
- Demonstrated superior BP-lowering efficacy compared to Losartan 50mg monotherapy⁷⁾
- Low-dose combination therapy is expected to minimize dose-dependent adverse reactions⁸⁾

For essential hypertension with various pathological causes, start with Amoprel!

The World's First Combination of Amlodipine Camlylate + Losartan Potassium

Amosartan Tab.
(Amlodipine camlylate/Losartan potassium)

The World's First Triple Combination of CCB/ARB/Chlorthalidone

Amosartan Plus Tab.
(Amlodipine/Losartan/Chlorthalidone)

The World's First Triple Combination of CCB/ARB/Rosuvastatin

Amosartan Q Tab.
(Amlodipine/Losartan/Rosuvastatin)

The World's First Quadruple Combination of CCB/ARB/Rosuvastatin/Ezetimibe

Amosartan XQ Tab.
(Amlodipine/Losartan/Rosuvastatin/Ezetimibe)

CV, cardiovascular; SCIE, science citation index expanded; R&D, research and development; CCB, calcium channel blocker; ARB, angiotensin II receptor blocker; BP, blood pressure
Ref. 1) Kim BK, et al. *Lancet*. 2022 Jul;400(10349):380-390. 2) UBIST D1 Sales data, (Based on the 2024 outpatient prescription expenditure). 3) McEvoy JW, et al. *Eur Heart J*. 2024 Oct;45(38):3912-4018. 4) Waelder B, et al. Antihypertensive agents: mechanisms of drug action, *Atlas of Heart Diseases*, 2001, pp. 144-161. 5) Mancía Chairperson G, et al. *J Hypertens*. 2023 Dec;41(12):1874-2071. 6) Data on file, [Protocol No. HM-APOLLO-301], CSR v1.0, 2024. 7) Data on file, [Protocol No. HM-APOLLO-302], CSR v1.0, 2024. 8) Law MR, et al. *BMJ*. 2003 Jun;326(7404):1427.

Hanmi Hanmi Pharm.



CONTENTS

Organization	5
Scientific Program Committee	6
Floor Plan	7
Program at a Glance	10
Program in Detail	13
Oral Presentation	62
Moderated Poster Presentation	65
E-Poster	71
Event Information	75
AI Interpretation Service	76
CME Credits (For Korean Participants)	78
Booth Exhibition	79
Sponsorship	81

ORGANIZATION


MEMBERS	NAME	AFFILIATION
2026 President	Sung Rae Kim	The Catholic University of Korea
2026 Vice President	Young Mi Park	Ewha Womans University
	Sung Nim Han	Seoul National University
Chairman	Sang-Hyun Kim	Seoul National University
Secretary General	Jae Hyoung Park	Korea University
	Seon Mee Kang	Soonchunhyang University
	Jeehoon Kang	Seoul National University
	Osung Kwon	The Catholic University of Korea
Vice-Secretary General	Ju Hyeon Kim	University of Ulsan
	Jaehyun Bae	Hallym University
	Young Woo Jang	Gachon University
	Yun Kyung Cho	University of Ulsan
Treasurer	Seong Hoon Choi	Hallym University
Director, Planning Committee	Byung Jin Kim	Sungkyunkwan University
Director, Scientific Program Committee	Hack-Lyoung Kim	Seoul National University
Director, Publication Committee	In-Kyung Jeong	Kyung Hee University
Director, Public Relations Committee	Min Kyong Moon	Seoul National University
Director, International Liaison Committee	Soon Jun Hong	Korea University
Director, Domestic Liaison Committee	Mihye Seo	Soonchunhyang University
Director, Insurance and Legislation Committee	Sang Yeub Lee	Chung-Ang University
Director, Medical Information Committee	Sang Min Park	Eulji University
Director, Social Contribution Committee	Jung-Woo Son	Yonsei University
Director, Committee of Ethics	Sang-Hak Lee	Yonsei University
Director, Education Committee	Jun Hwa Hong	Eulji University
Director, Clinical Practice Guideline Committee	Hyun-Jin Kim	Hanyang University
Director, Clinic Research Committee	Jong-Chan Youn	The Catholic University of Korea
Director, Basic Research Committee	Hyoung Kyu Kim	Inje University
Director, Food and Nutrition Committee	Min-Jeong Shin	Korea University
Director of Special Affairs	Eun-Jung Rhee	Sungkyunkwan University
	Hyun Kang	Chung-Ang University
	Hyuk-Sang Kwon	The Catholic University of Korea
	Junghyun Noh	Inje University
	Sungha Park	Yonsei University
	Hyeong Kyu Park	Soonchunhyang University
	Keeho Song	Konkuk University
	Sung Gyun Ahn	Yonsei University
	JiHyun Ahn	Korea Medical Institute
Director without Portfolio	Sang-Rok Lee	Jeonbuk National University
	Seung-Hwan Lee	The Catholic University of Korea
	Wang-Soo Lee	Chung-Ang University
	Jun-Hee Lee	Hallym University
	Sang Ho Jo	Hallym University
	Sung Hee Choi	Seoul National University
	Jung-Kyu Han	Seoul National University
	Young Joon Hong	Chonnam National University
Auditor	Cheol-Young Park	Sungkyunkwan University
	Woo Je Lee	University of Ulsan



SCIENTIFIC PROGRAM COMMITTEE

MEMBERS	NAME	AFFILIATION
Director	Hack-Lyoung Kim	Seoul National University
Associates	Wonjin Kim	CHA University
	Hyun-Jin Kim	Hanyang University
	Ye Seul Yang	Seoul National University
	Jaehoon Chung	Gachon University
	Hyun Ju Kang	Kyungpook National University
	Eu Jeong Ku	Seoul National University
	KyeongJin Kim	Inha University
	Kyuhoo Kim	The Catholic University of Korea
	Bum Joon Kim	University of Ulsan
	Jeong-Min Kim	Seoul National University
	Hyue Mee Kim	Chung-Ang University
	Jun Namkung	Yonsei University
	Young-Sang Lyu	Chosun University
	Dahyun Park	Korea University
	Yong Hyun Park	Pusan National University
	Hyun-Woong Park	Chungnam National University
	SungA Bae	Yonsei University
	Jae Hyun Bae	Seoul National University
	Mihye Seo	Soonchunhyang University
	Yeoree Yang	The Catholic University of Korea
Members	Jin Kyung Oh	Chungnam National University
	Jong Shin Woo	Kyung Hee University
	Jee Hee Yoo	Chung-Ang University
	Min Kyung Lee	Hanyang University
	Seung Hun Lee	Chonnam National University
	Hokyou Lee	Yonsei University
	Jeong Yoon Jang	Gyeongsang National University
	Ki-Hyun Jeon	Seoul National University
	Jae-Han Jeon	Kyungpook National University
	Mi-Hyang Jung	The Catholic University of Korea
	Su Myung Jung	Sungkyunkwan University
	Garam Jo	Hannam University
	Iksung Jo	Yonsei University
	Hyun Sung Joh	Seoul National University
	Jung-Joon Cha	Korea University
	Jong Han Choi	Konkuk University
	Hun Jee Choe	Hallym University
	Jun Hwa Hong	Eulji University
	Sang-Hyun Kim	Seoul National University
Advisors	Hyeon Chang Kim	Yonsei University
	Hyoung Kyu Kim	Inje University
	Oh-Yoen Kim	Dong-A University
	Yongseek Park	Kyung Hee University
	Cheol-Young Park	Sungkyunkwan University
	Min-Jeong Shin	Korea University
	Han-Mo Yang	Seoul National University
	Jong-Chan Youn	The Catholic University of Korea
	Sang-Hak Lee	Yonsei University
	Woo Je Lee	University of Ulsan
	Eun-Jung Rhee	Sungkyunkwan University
	In-Kyung Jeong	Kyung Hee University
	Kyung Mook Choi	Korea University

FLOOR PLAN



Sponsorship	Booth No.	Corporate
Diamond	1	Hanmi Pharm
	2	JW Pharm
Platinum	1	Organon
	2	Daewoong Pharm
	3	GSK
	4	Novartis
Gold	1	Viartis



FLOOR PLAN

5F, Conrad Seoul



FLOOR PLAN

6F, Conrad Seoul



Sponsorship	Booth No.	Corporate
Gold	2	Yuhan
	3	Jeil Pharm
	4	Daiichi Sankyo
Silver	1	Amgen
	2	Chong Kun Dang
	3	Dong-A ST
	4	GC Biopharma Corp.
	5	Hanlim Pharm
	6	HK inno,N

Sponsorship	Booth No.	Corporate
Bronze	1	Alvogen Korea
	2	Celltrion Pharm
	3	Yooyoung Pharm
	4	Hyundai Pharm
	5	SK Chemical
	6	Sanofi
	7	LG Chemical
	8	Boryung
	9	Otsuka Pharm
	10	Daewon Pharm
	11	Novo Nordisk
	12	Samjin Pharm
	13	Ahngook Pharm

Sponsorship	Booth No.	Corporate
Exhibition Booth	1	Korea United Pharm
	2	BCWorld Pharm
	3	Myungmoon Pharm
	4	Menarini
	5	Ildong Pharm
	6	Abbott
	7	Kuhnle Pharm
	8	Boehringer Ingelheim
	9	Lilly
	10	Daewoong Bio Inc
	11	IL-Yang Pharm
	12	Firson
	13	Shinpoong Pharm
	14	Dongwha Pharm



PROGRAM AT A GLANCE

[Day 1] September 10(Thu), 2026

(K): Korean Session
(K+E): Korean & English Session (The language of each lecture may differ within the same session.)

	Room 1 (Grand Ballroom 3, 3F)	Room 2 (Grand Ballroom 2, 3F)	Room 3 (Grand Ballroom 1, 3F)	Room 4 (Park Ballroom 3, 5F)
12:00-	Registration			
13:00-14:30	Symposium 1 Nutritional Immunometabolism in Atherosclerosis	Symposium 2 (K) From Biobank to Biology: Integrative Platforms for Cardiometabolic Discovery	Symposium 3 Inflammation in ASCVD: From LDL Lowering to Immune Modulation	Symposium 4 *Session Time: 13:00-14:00 Publication Committee Session: JLA Award for Outstanding Article
14:30-16:00	Oral Presentation 1	Symposium 5 FH/Severe Dyslipidemia: Optimizing FH Management	IHA-KSoLA Joint Symposium Optimizing Lipid-Lowering Strategies: Facing Challenges in Asian High-Risk Patients	Symposium 6 Neurocardiometabolic Benefits of GLP1 RA and SGLT2 Inhibitors
16:00-16:10	Break			
16:10-17:40	Symposium 7 Real-world LDL-C Management: From Guideline to Prescription	JAS-KSoLA Joint Symposium Comprehensive Lipid Management in East Asians: Integrating LDL-C Optimization, Residual Risk, and Genetic Factors	Symposium 8 Metabolic Regulators of Lipid Metabolism: From Mechanisms to Cardiovascular Outcomes	Symposium 9 KSN-KSoLA Joint Symposium Chronic Kidney Disease and Atherosclerosis
17:40-	Welcome Reception (Lobby, Studio 4-7, 6F)			

PROGRAM AT A GLANCE

[Day 2] September 11(Fri), 2026

(K): Korean Session
(K+E): Korean & English Session (The language of each lecture may differ within the same session.)

	Room 1 (Grand Ballroom 3, 3F)	Room 2 (Grand Ballroom 2, 3F)	Room 3 (Grand Ballroom 1, 3F)	Room 4 (Park Ballroom 3, 5F)	Room 5 (Studio 2,3, 6F)
07:30-08:30	Breakfast Symposium 1 (K+E)	Breakfast Symposium 2	Breakfast Symposium 3	Breakfast Symposium 4	
08:30-10:00	Oral Presentation 2	Symposium 10 New Frontiers in Lipid Lowering: Beyond Statins (New Drugs 1)	Symposium 11 Lipid-lowering Therapy in Complex Clinical Settings: HIV, Cancer, and Chronic Kidney Disease	Symposium 12 KPS-KSoLA Joint Symposium Bridging Cellular Physiology and Atherogenic Lipids	
10:00-10:10	Break				
10:10-10:20	Opening Address				
10:20-11:00	Plenary Lecture 1 Lipoprotein(a): the next frontier in cardiovascular prevention				
11:00-11:40	Special Lecture 1 (K) 도자기로 보는 한국 전통 미술의 생명력 (The vitality of traditional Korean art through ceramics)				
11:45-12:45	Luncheon Symposium 1 (K)	Luncheon Symposium 2	Luncheon Symposium 3	Luncheon Symposium 4 (K)	Luncheon Symposium 5
12:45-13:45	Poster Presentation Session 1 (Studio 5, 6, 7, 6F)				
	Symposium 13 (K) 2026 KSoLA Awards for Scientific Excellence & Digital Health Media and Ethics	Symposium 14 Sex-specific Lipid Biology and Cardiometabolic Risk across the Lifespan			
13:45-15:15	Symposium 15 Official Launch of the 2026 KSoLA Guidelines for the Management of Dyslipidemia	VAS-KSoLA Joint Symposium Residual Cardiovascular Risk Beyond LDL-C: The Emerging Role of Lipoprotein(a) in Asia	Symposium 16 Evolution of High-Risk Coronary Plaques: From Detection to Prevention	Symposium 17 Metabolic Dysfunction, Fatty Liver, and Atherosclerosis	
15:20-16:00	Plenary Lecture 2 Closing the gap between guidelines and reality in dyslipidemia management				
16:00-16:10	Break				
16:10-17:40	Symposium 18 Intensive LDL-C Lowering in Primary Prevention	Symposium 19 Next-generation Lipid-lowering Therapies: CETP, APOC3, and ANGPTL3 Inhibition (New Drugs 2)	Symposium 20 Residual Cardiovascular Risk: Beyond LDL to Inflammation and Novel Targets	Symposium 21 KSSO-KSoLA Joint Symposium Atherogenic Obesity: Beyond BMI to Lipid Dysfunction	



PROGRAM AT A GLANCE

[Day 3] September 12(Sat), 2026

(K): Korean Session

(K+E): Korean & English Session (The language of each lecture may differ within the same session.)

	Room 1 (Grand Ballroom 3, 3F)	Room 2 (Grand Ballroom 2, 3F)	Room 3 (Grand Ballroom 1, 3F)	Room 4 (Park Ballroom 3, 5F)
07:50-08:50	Breakfast Symposium 5	Breakfast Symposium 6	Breakfast Symposium 7	Breakfast Symposium 8
08:50-10:20	Oral Presentation 3	TSLA-KSoLA Joint Symposium Contemporary Management of Residual Cardiovascular Risk in Asia	Symposium 22 Lp(a) beyond the Known: From Metabolic Pathways to Clinical Translation	MSA-KSoLA Joint Symposium From Diversity to Action: Ethnicity, Genetics, and Closing the Treatment Gap in Asian Dyslipidemia
10:20-10:40	Coffee Break			
10:40-11:20	Plenary Lecture 3 Beyond LDL-C lowering: strategies for maximizing residual ASCVD risk reduction			
11:20-12:00	Plenary Lecture 4 Perspective on residual risk, inflammation, and atherosclerosis: from epidemiology to precision prevention			
12:00-13:00	Luncheon Symposium 6	Luncheon Symposium 7	Luncheon Symposium 8	
13:00-14:00	Poster Presentation Session 2 (Studio 5, 6, 7, 6F)			
	Symposium 23 KSH-KSoLA Joint Symposium Hypertension, Lipids, and Vascular Aging: Integrated Cardiovascular Risk Management	Symposium 24 KSCVH-KSoLA Joint Symposium Beyond Stenting: Contemporary Management of Residual Coronary Risk	Symposium 25 KDA-KSoLA Joint Symposium Integrated Cardiometabolic Risk Management in Diabetes	Special Lecture 2 *Session Time: 13:20-13:50 Atherosclerosis and atherosclerotic cardiovascular disease in Asia: the knowledge gap for the determinants
14:00-14:10	Break			
14:10-15:40	Symposium 26 Integrated Cardiovascular-kidney- metabolic Care: A Multidisciplinary Approach to CKM Syndrome	Symposium 27 AI-driven Innovations in Atherosclerosis	Symposium 28 Primary Prevention in Cardiovascular Disease: Beyond Traditional Risk Factors	Symposium 29 KES-KSoLA Joint Symposium Lipid Metabolism Across Endocrine Disorders: From Mechanism to Clinical Practice
15:40-17:10	Symposium 30 Neural and Genetic Control of Eating Behavior and Cardiometabolic Health	EAS-KSoLA Joint Symposium Bridging Europe and Korea in Dyslipidemia Management: Guidelines, Gaps, and Future Directions	Symposium 31 From Cells to Systems: Integrated Control of Cardiometabolic Health	Symposium 32 Environmental Cardiovascular Risk
17:10-	Closing Ceremony (Room 1,2,3, 3F)			

PROGRAM IN DETAIL

Symposium 1

Sep 10(Thu) 13:00-14:30 | Room 1 (3F, Conrad Seoul)

Nutritional Immunometabolism in Atherosclerosis

CHAIRPERSONS : Myoung Sook Lee (Sungshin Women's University, Republic of Korea)
Sung Nim Han (Seoul National University, Republic of Korea)



- 13:00-13:20 Gut microbiota remodeling in infection and inflammation
Eun-Kyeong Jo (Chungnam National University, Republic of Korea)
- 13:20-13:40 Ketogenic adaptation to intermittent fasting: implications for nutritional immunometabolism
Kyoung-Han Kim (University of Ottawa, Canada)
- 13:40-14:00 Spatiotemporal immune activation drives metabolic quiescence in brown adipose tissue
Su Myung Jung (Sungkyunkwan University, Republic of Korea)
- 14:00-14:30 Panel Discussion
Hyunju Kang (Kyungpook National University, Republic of Korea)
Jun Namkung (Yonsei University, Republic of Korea)
Chan Joo Lee (Yonsei University, Republic of Korea)

**Symposium 2 (K)**

Sep 10(Thu) 13:00-14:30 | Room 2 (3F, Conrad Seoul)

From Biobank to Biology: Integrative Platforms for Cardiometabolic Discovery

CHAIRPERSONS : Chi Dae Kim (Pusan National University, Republic of Korea)
 Young-Guen Kwon (Curacle Advanced Institute of Technology, Republic of Korea)



- 13:00-13:20 **Biobank resources for human metabolic and vascular research**
 Hyun-Joung Lim (National Institute of Health, Republic of Korea)
- 13:20-13:40 **Leveraging biobank platforms to study cardiometabolic physiology and disease**
 Heiko Bugger (Medical University of Graz, Austria)
- 13:40-14:00 **Integrative analysis of metabolic dysfunction**
 Young Yang (Sookmyung Women's University, Republic of Korea)
- 14:00-14:30 **Panel Discussion**
 Yongseek Park (Kyung Hee University, Republic of Korea)
 Jun Hwan Cho (Chung-Ang University, Republic of Korea)
 Jae-Hoon Choi (Hanyang University, Republic of Korea)

**Symposium 3**

Sep 10(Thu) 13:00-14:30 | Room 3 (3F, Conrad Seoul)

Inflammation in ASCVD: From LDL Lowering to Immune Modulation

CHAIRPERSONS : Young Joon Hong (Chonnam National University, Republic of Korea)
 Weon Kim (Kyung Hee University, Republic of Korea)



- 13:00-13:18 **LDL versus inflammation: what remains after aggressive lipid lowering?**
 Osung Kwon (The Catholic University of Korea, Republic of Korea)
- 13:18-13:36 **Emerging anti-inflammatory therapies in ASCVD: canakinumab, NLRP3 inhibitors, and beyond**
 SungA Bae (Yonsei University, Republic of Korea)
- 13:36-13:54 **Colchicine for secondary prevention in ASCVD**
 Dae Young Cheon (Hallym University, Republic of Korea)
- 13:54-14:12 **Immune mechanisms of residual cardiovascular risk: from oxidation-specific epitopes to therapeutic targets**
 Christoph J. Binder (Medical University of Vienna, Austria)
- 14:12-14:30 **Panel Discussion**
 Ung Kim (Yeungnam University, Republic of Korea)
 Chang-Hoon Woo (Yeungnam University, Republic of Korea)
 Jong-Chan Youn (The Catholic University of Korea, Republic of Korea)



Symposium 4

Sep 10(Thu) 13:00-14:00 | Room 4 (5F, Conrad Seoul)

Publication Committee Session: JLA Award for Outstanding Article

CHAIRPERSONS : In-Kyung Jeong (Kyung Hee University, Republic of Korea)
Hyun Kang (Chung-Ang University, Republic of Korea)



- 13:00-13:15 **Arterial tissue gene expression associated with telomere length attrition in coronary artery disease**
Rajkumar Dorajoo (Genome Institute of Singapore, Singapore)
- 13:15-13:30 **Administration of sodium-glucose cotransporter-2 inhibitors following acute myocardial infarction: a systematic review, meta-analysis, and meta-regression of randomized trials**
Timotius Ivan Hariyanto (Universitas Airlangga, Indonesia)
- 13:30-13:45 **Sex differences in the diagnosis and treatment of Japanese patients with familial hypercholesterolemia**
Hayato Tada (Kanazawa University, Japan)
- 13:45-14:00 **Tigloylgomisin P inhibits endothelial inflammation via NFκB and Smad1/5/9 pathway regulation**
Sanguk Yun (Inje University, Republic of Korea)

Symposium 5

Sep 10(Thu) 14:30-16:00 | Room 2 (3F, Conrad Seoul)

FH/Severe Dyslipidemia: Optimizing FH Management

CHAIRPERSONS : Sang-Hak Lee (Yonsei University, Republic of Korea)
Hayato Tada (Kanazawa University, Japan)



- 14:30-14:48 **Refined risk assessment in FH**
Sayaka Funabashi (Kyorin University, Japan)
- 14:52-15:10 **Cause of death in FH**
Chan Joo Lee (Yonsei University, Republic of Korea)
- 15:14-15:32 **Experience on new drugs for FH: including lomitapide & evinacumab**
Hayato Tada (Kanazawa University, Japan)
- 15:36-15:54 **Genome editing for precision medicine**
HyongBum Kim (Yonsei University, Republic of Korea)
- Panel**
Sung Hee Choi (Seoul National University, Republic of Korea)



IHA-KSoLA Joint Symposium

Sep 10(Thu) 14:30-16:00 | Room 3 (3F, Conrad Seoul)

Optimizing Lipid-Lowering Strategies: Facing Challenges in Asian High-Risk Patients

CHAIRPERSONS : Ick Mo Chung (Ewha Womans University, Republic of Korea)
Ade Meidian Ambari (University of Indonesia, Indonesia)



- 14:30-14:50 **The race to the bottom: intensive LDL-C lowering in very high-risk Asian patients**
Ade Meidian Ambari (University of Indonesia, Indonesia)
- 14:50-15:10 **Combination therapy in high-risk patients: early vs stepwise approach**
Han Na Jung (Hallym University, Republic of Korea)
- 15:10-15:30 **Practical approaches to statin intolerance: from clinical trials to real-world solutions**
Jung-Joon Cha (Korea University, Republic of Korea)
- 15:30-16:00 **Panel Discussion**
Kyung An Kim (The Catholic University of Korea, Republic of Korea)
Hyeonju Jeong (Hanyang University, Republic of Korea)
Hun Jee Choe (Hallym University, Republic of Korea)



Symposium 6

Sep 10(Thu) 14:30-16:00 | Room 4 (5F, Conrad Seoul)

Neurocardiometabolic Benefits of GLP1 RA and SGLT2 Inhibitors

CHAIRPERSONS : Geun Sik Hong (Inje University, Republic of Korea)
Kwang-Yeol Park (Chung-Ang University, Republic of Korea)



- 14:30-14:50 **GLP1 RA for stroke prevention**
Kang-Ho Choi (Chonnam National University, Republic of Korea)
- 14:50-15:10 **SGLT2 inhibitor for stroke survivors**
Jeong-Min Kim (Seoul National University, Republic of Korea)
- 15:10-15:30 **GLP-1 receptor agonists in Alzheimer's disease**
Sang-Won Han (Seoul National University, Republic of Korea)
- 15:30-16:00 **Panel Discussion**
Bum Joon Kim (University of Ulsan, Republic of Korea)
Hack-Lyoung Kim (Seoul National University, Republic of Korea)
Se-eun Park (Sungkyunkwan University, Republic of Korea)



Symposium 7

Sep 10(Thu) 16:10-17:40 | Room 1 (3F, Conrad Seoul)

Real-world LDL-C Management: From Guideline to Prescription

CHAIRPERSONS : Youngkeun Ahn (Chonnam National University, Republic of Korea)
Min Kyong Moon (Seoul National University, Republic of Korea)



- 16:10-16:28 **Choosing the right combination therapy: statin, ezetimibe, PCSK9 inhibitor, or beyond?**
Kyung Hoon Cho (Chonnam National University, Republic of Korea)
- 16:28-16:46 **Korean Fact Sheet: Current status of LDL-C control from general population to high-risk groups**
Ye Seul Yang (Seoul National University, Republic of Korea)
- 16:46-17:04 **Korean Fact Sheet: Real-world utilization of lipid-lowering agents**
Kyuhoo Kim (The Catholic University of Korea, Republic of Korea)
- 17:04-17:22 **Why are LDL-C targets still unmet? common errors and practical solutions in the clinic**
Sang Yeub Lee (Chung-Ang University, Republic of Korea)
- 17:22-17:40 **Panel Discussion**
Young Soo Lee (Daegu Catholic University, Republic of Korea)
Jun Hwan Cho (Chung-Ang University, Republic of Korea)
Sangmo Hong (Hanyang University, Republic of Korea)

JAS-KSoLA Joint Symposium

Sep 10(Thu) 16:10-17:40 | Room 2 (3F, Conrad Seoul)

Comprehensive Lipid Management in East Asians: Integrating LDL-C Optimization, Residual Risk, and Genetic Factors

CHAIRPERSONS : Sung Rae Kim (The Catholic University of Korea, Republic of Korea)
Jae Hyoung Park (Korea University, Republic of Korea)



- 16:10-16:28 **Do East Asians need lower statin intensity? ethnic differences in LDL-C response and safety**
Eun Jeong Cho (Chung-Ang University, Republic of Korea)
- 16:28-16:46 **Why TG is important in Asians?**
Daisaku Masuda (Rinku General Medical Center, Japan)
- 16:46-17:04 **Genetic stratification and treatment response in Korean severe hypertriglyceridemia: a prospective multicenter registry study**
Hun Jee Choe (Hallym University, Republic of Korea)
- 17:04-17:22 **Chylomicronemia: past, present and future**
Hiroaki Okazaki (Teikyo University, Japan)
- 17:22-17:40 **Panel Discussion**
Osung Kwon (The Catholic University of Korea, Republic of Korea)
Gyu Chul Oh (The Catholic University of Korea, Republic of Korea)
Dae Young Cheon (Hallym University, Republic of Korea)



Symposium 8

Sep 10(Thu) 16:10-17:40 | Room 3 (3F, Conrad Seoul)

Metabolic Regulators of Lipid Metabolism: From Mechanisms to Cardiovascular Outcomes

CHAIRPERSONS : Eun Gyoung Hong (Hallym University, Republic of Korea)
Chul Sik Kim (Yonsei University, Republic of Korea)



- 16:10-16:30 **Sex differences in lymphatic function and atherosclerosis outcomes**
Catherine Martel (University of Montreal, Canada)
- 16:30-16:50 **Tirzepatide and cardiometabolic outcomes: implications of dual GLP-1/GIP agonism**
Yun Kyung Cho (University of Ulsan, Republic of Korea)
- 16:50-17:10 **Effects of SGLT2 inhibitors on lipid metabolism: mechanisms and clinical implications**
Jun Hwa Hong (Eulji University, Republic of Korea)
- 17:10-17:40 **Panel Discussion**
Shinae Kang (Yonsei University, Republic of Korea)
JiHyun Ahn (Korea Medical Institute, Republic of Korea)
Jung-Joon Cha (Korea University, Republic of Korea)



Symposium 9 - KSN-KSoLA Joint Symposium

Sep 10(Thu) 16:10-17:40 | Room 4 (5F, Conrad Seoul)

Chronic Kidney Disease and Atherosclerosis

CHAIRPERSONS : Sang-Hyun Kim (Seoul National University, Republic of Korea)
Bum Soon Choi (The Catholic University of Korea, Republic of Korea)



- 16:10-16:30 **Lipid abnormalities in CKD**
Hong Sang Choi (Chonnam National University, Republic of Korea)
- 16:30-16:50 **Why patients with CKD develop accelerated atherosclerosis**
Cheol Ho Park (Yonsei University, Republic of Korea)
- 16:50-17:10 **Cardiovascular prevention in CKD: an endocrinologist's perspective**
Eun Roh (Seoul National University, Republic of Korea)
- 17:10-17:40 **Panel Discussion**
Wonjin Kim (CHA University, Republic of Korea)
Ji Won Ryu (Seoul National University, Republic of Korea)
Eun Hui Bae (Chonnam National University, Republic of Korea)



Breakfast Symposium 1 (K+E)

Sep 11 (Fri) 07:30-08:00 | Room 1 (3F, Conrad Seoul)

Amgen, Hanlim Pharm

CHAIRPERSONS : Myung-gon Kim (Catholic Kwandong University, Republic of Korea)
Hee-Yeol Kim (Incheon Sejong Hospital, Republic of Korea)



07:30-07:45 **Evolving LDL-C management: guidelines and the role of evolocumab**

Sang Min Park (Eulji University, Republic of Korea)

07:45-08:00 **Is LDL-C goal attainment enough? pitavastatin/fenofibrate in mixed dyslipidemia**

Jae Hyun Bae (Seoul National University, Republic of Korea)

Breakfast Symposium 2

Sep 11 (Fri) 07:30-08:00 | Room 2 (3F, Conrad Seoul)

Jeil Pharmaceutical

CHAIRPERSON : Jae Hyoung Park (Korea University, Republic of Korea)



07:30-07:50 **Bridging guidelines and practice: strategic implementation of combination therapy in lipid management**

Inki Moon (Soonchunhyang University, Republic of Korea)

Breakfast Symposium 3

Sep 11 (Fri) 07:30-08:00 | Room 3 (3F, Conrad Seoul)

Yuhan

CHAIRPERSON : Jeong-Taek Woo (Kyung Hee University, Republic of Korea)



07:30-07:50 **Paving the road for optimal LDL-C management: new evidence on intensive LDL-C targeting from the Ez-PAVE trial**

Yong-Joon Lee (Yonsei University, Republic of Korea)

Breakfast Symposium 4

Sep 11 (Fri) 07:30-08:00 | Room 4 (5F, Conrad Seoul)

Dong-A ST, HK inno.N

CHAIRPERSONS : Byung Ryul Cho (Kangwon National University, Republic of Korea)
Bong-Ki Lee (Kangwon National University, Republic of Korea)



07:30-07:45 **The role of DPP-4 inhibitors in Korean diabetes care: focusing on K-evidence**

Yun Kyung Cho (University of Ulsan, Republic of Korea)

07:45-08:00 **The smaller the better: rovaset**

Jeehoon Kang (Seoul National University, Republic of Korea)



Symposium 10

Sep 11 (Fri) 08:30-10:00 | Room 2 (3F, Conrad Seoul)

New Frontiers in Lipid Lowering: Beyond Statins (New Drugs 1)

CHAIRPERSONS : Sang-Hak Lee (Yonsei University, Republic of Korea)
Sungha Park (Yonsei University, Republic of Korea)



08:30-08:50 **Bempedoic acid: LDL-C lowering beyond statins - evidence and clinical role**

Chewan Lim (Catholic Kwandong University, Republic of Korea)

08:50-09:10 **Optimizing non-statin therapy: PCSK9 inhibitors and inclisiran**

Kyung-Hee Kim (Incheon Sejong Hospital, Republic of Korea)

09:10-09:30 **Emerging Lp(a)-lowering therapies: siRNA, ASO, and beyond**

Yu-Chen Wang (Asia University, Taiwan)

09:30-10:00 **Panel Discussion**

Gyu Chul Oh (The Catholic University of Korea, Republic of Korea)

Ji-Yong Jang (National Health Insurance Service Ilsan Hospital, Republic of Korea)

Yun Kyung Cho (University of Ulsan, Republic of Korea)



Symposium 11

Sep 11 (Fri) 08:30-10:00 | Room 3 (3F, Conrad Seoul)

Lipid-lowering Therapy in Complex Clinical Settings: HIV, Cancer, and Chronic Kidney Disease

CHAIRPERSONS : Junghyun Noh (Inje University, Republic of Korea)
Jung-Sun Kim (Yonsei University, Republic of Korea)



08:30-08:48 **Lipid-lowering therapy in people living with HIV (PLWH)**

So Ree Kim (Korea University, Republic of Korea)

08:48-09:06 **Lipid-lowering therapy in cancer patients and survivors**

Hiroshi Akazawa (Kanazawa Medical University, Japan)

09:06-09:24 **Lipid-lowering therapy in patients with CKD**

Eun Sil Koh (The Catholic University of Korea, Republic of Korea)

09:24-09:42 **Cardiovascular prevention in hemodialysis: is omega-3 back?**

Sang Ho Jo (Hallym University, Republic of Korea)

09:42-10:00 **Panel Discussion**

Sang Yong Kim (Chosun University, Republic of Korea)

Ji Woong Yoo (Hallym University, Republic of Korea)

Mi-Hyang Jung (The Catholic University of Korea, Republic of Korea)



Symposium 12 - KPS-KSoLA Joint Symposium

Sep 11 (Fri) 08:30-10:00 | Room 4 (5F, Conrad Seoul)

Bridging Cellular Physiology and Atherogenic Lipids

CHAIRPERSONS : Yong Sook Kim (Chonnam National University, Republic of Korea)
Hyoung Kyu Kim (Inje University, Republic of Korea)



- 08:30-08:50 **Ion channels in atherosclerosis: from calcium flux to vascular dysfunction**
Sung Joon Kim (Seoul National University, Republic of Korea)
- 08:50-09:10 **Energy metabolism and lipid oxidation in cardiometabolic pathophysiology**
Jin Han (Inje University, Republic of Korea)
- 09:10-09:30 **Lp(a): from lipoprotein biology to atherosclerotic cardiovascular disease**
Jung-Woo Son (Yonsei University, Republic of Korea)
- 09:30-10:00 **Panel Discussion**
Nari Kim (Inje University, Republic of Korea)
Jong-Gil Park (Korea Research Institute of Bioscience and Biotechnology, Republic of Korea)
Dong Kyu Choi (Kyungpook National University, Republic of Korea)



Plenary Lecture 1

Sep 11 (Fri) 10:20-11:00 | Room 1,2,3 (3F, Conrad Seoul)

CHAIRPERSON : Sung Rae Kim (The Catholic University of Korea, Republic of Korea)



- 10:20-11:00 **Lipoprotein(a): the next frontier in cardiovascular prevention**
Sotirios Tsimikas (University of California, San Diego, USA)

Special Lecture 1 (K)

Sep 11 (Fri) 11:00-11:40 | Room 1,2,3 (3F, Conrad Seoul)

CHAIRPERSON : Jae Hyoung Park (Korea University, Republic of Korea)



- 11:00-11:40 **도자기로 보는 한국 전통 미술의 생명력 (The vitality of traditional Korean art through ceramics)**
Ae-Ryung Lee (National Museum of Korea, Republic of Korea)



Luncheon Symposium 1 (K)

Sep 11 (Fri) 11:45-12:15 | Room 1 (3F, Conrad Seoul)

Organon

CHAIRPERSON : Young-Bae Park (Seoul National University, Republic of Korea)



11:45-12:00 **Start early: upfront combination therapy for faster LDL-C goal attainment in the CKM era**

Soo-Jin Kim (Kosin University, Republic of Korea)

12:00-12:15 **Start strong: elevating LDL-C management in ASCVD with high-dose atorvastatin plus ezetimibe**

Jeehoon Kang (Seoul National University, Republic of Korea)

Luncheon Symposium 2

Sep 11 (Fri) 11:45-12:15 | Room 2 (3F, Conrad Seoul)

Hanmi Pharmaceutical

CHAIRPERSONS : Kyong Soo Park (Konkuk University, Republic of Korea)
Myung A Kim (Jeju National University, Republic of Korea)



11:45-12:00 **Beyond the statin, ROSUZET; start early, switch now**

Gyu Chul Oh (The Catholic University of Korea, Republic of Korea)

12:00-12:15 **Be the standard ROSUZET; evidence-driven lipid management**

Wonjin Kim (CHA University, Republic of Korea)

Luncheon Symposium 3

Sep 11 (Fri) 11:45-12:15 | Room 3 (3F, Conrad Seoul)

JW Pharmaceutical

CHAIRPERSON : Hyo-Soo Kim (Seoul National University, Republic of Korea)



11:45-12:00 **Integrated management of hypertension and dyslipidemia for cardiovascular disease prevention**

Minjeong Kim (Ewha Womans University, Republic of Korea)

12:00-12:15 **Management of inadequately controlled patients with diabetes mellitus**

Hae Kyung Kim (Yonsei University, Republic of Korea)

Luncheon Symposium 4 (K)

Sep 11 (Fri) 11:45-12:15 | Room 4 (5F, Conrad Seoul)

Novartis

CHAIRPERSON : Moon-Kyu Lee (Eulji University, Republic of Korea)



11:45-12:00 **Protecting the vulnerable period: early and sustained LDL-C control with inclisiran**

In Tae Jin (Yonsei University, Republic of Korea)

12:00-12:15 **Proven in the real world: consistent LDL-C control with inclisiran**

Seok Oh (Chonnam National University, Republic of Korea)

Luncheon Symposium 5

Sep 11 (Fri) 11:45-12:15 | Room 5 (6F, Conrad Seoul)

Daewoong

CHAIRPERSON : Hyun Ho Shin (Asan Chungmu Hospital, Republic of Korea)



11:45-12:00 **Clinical updates in dyslipidemia: positioning baroezet for optimal patient care**

Jun Sung Moon (Yeungnam University, Republic of Korea)

12:00-12:15 **Strategies for high-risk dyslipidemia patients focusing on ASCVD**

Sang Yoon Lee (Sungkyunkwan University, Republic of Korea)



Symposium 13 (K)

Sep 11 (Fri) 12:45-13:40 | Room 1 (3F, Conrad Seoul)

2026 KSoLA Awards for Scientific Excellence & Digital Health Media and Ethics

CHAIRPERSONS : Sung Rae Kim (The Catholic University of Korea, Republic of Korea)
Sang-Hyun Kim (Seoul National University, Republic of Korea)



- 12:45-12:50 2026 KSoLA Award Ceremony for Scientific Excellence
- 12:50-12:55 2026 KSoLA Award Ceremony for Young Investigator
- 12:55-13:15 The quiet signal, no longer - triglyceride at the crossroads of insulin resistance and cardiometabolic risk
Cheol-Young Park (Sungkyunkwan University, Republic of Korea)
- 13:15-13:20 Q&A
- 13:20-13:40 How reliable is statin information on Korean YouTube? validating AI-assisted reliability assessment against expert raters
Ilhak Lee (Yonsei University, Republic of Korea)
- 13:40-13:45 Q&A



Symposium 14

Sep 11 (Fri) 12:45-13:45 | Room 2 (3F, Conrad Seoul)

Sex-specific Lipid Biology and Cardiometabolic Risk across the Lifespan

CHAIRPERSONS : Mi-Seung Shin (Gachon University, Republic of Korea)
Jun-Hee Lee (Hallym University, Republic of Korea)



- 12:45-13:00 Sex differences in lipids and lipoproteins and residual cardiovascular risk: beyond LDL cholesterol
Soo-Jin Kim (Kosin University, Republic of Korea)
- 13:00-13:15 Early-onset dyslipidemia in young adults: screening strategies and lifetime ASCVD risk assessment
Jaehyun Bae (Hallym University, Republic of Korea)
- 13:15-13:30 Menopause and cardiometabolic transition: optimizing lipid management in midlife women
In-Jeong Cho (Ewha Womans University, Republic of Korea)
- 13:30-13:45 Panel Discussion
Hack-Lyoung Kim (Seoul National University, Republic of Korea)
Ye Seul Yang (Seoul National University, Republic of Korea)
Seok Oh (Chonnam National University, Republic of Korea)



Symposium 15

Sep 11 (Fri) 13:45-15:15 | Room 1 (3F, Conrad Seoul)

Official Launch of the 2026 KSoLA Guidelines for the Management of Dyslipidemia

CHAIRPERSONS : Sang-Hyun Kim (Seoul National University, Republic of Korea)
Woo Je Lee (University of Ulsan, Republic of Korea)



- 13:45-13:50 **What's new in the 2026 Korean guidelines for the management of dyslipidemia**
Hyun-Jin Kim (Hanyang University, Republic of Korea)
- 13:50-14:08 **Korean epidemiology and risk modifiers for establishing LDL-C goal strategies**
Jong Han Choi (Konkuk University, Republic of Korea)
- 14:08-14:26 **Practical algorithm for intensive lipid lowering therapy in the 2026 Korean guidelines**
Jaehoon Chung (Gachon University, Republic of Korea)
- 14:26-14:44 **Nutritional management and lifestyle modification tailored to the Korean dietary pattern**
Garam Jo (Hannam University, Republic of Korea)
- 14:44-15:02 **Optimized lipid management for special populations**
Byung Sik Kim (Hanyang University, Republic of Korea)
- 15:02-15:15 **Panel Discussion**
Hyun-Jin Kim (Hanyang University, Republic of Korea)
Eunju Park (Kyungnam University, Republic of Korea)
Jee Hee Yoo (Chung-Ang University, Republic of Korea)
Hye Moon Chung (Kyung Hee University, Republic of Korea)



VAS-KSoLA Joint Symposium

Sep 11 (Fri) 13:45-15:15 | Room 2 (3F, Conrad Seoul)

Residual Cardiovascular Risk Beyond LDL-C: The Emerging Role of Lipoprotein(a) in Asia

CHAIRPERSONS : Donghoon Choi (Yonsei University, Republic of Korea)
Kyung Woo Park (Seoul National University, Republic of Korea)



- 13:45-14:05 **Lipoprotein(a) in Korean patients: real-world data, cardiovascular risk, and clinical implications**
Sang Min Park (Eulji University, Republic of Korea)
- 14:05-14:25 **Lipoprotein(a) and coronary atherosclerosis in Vietnam: real-world data and emerging cardiovascular risk**
Anh Tien Hoang (Hue University, Vietnam)
- 14:25-14:45 **Measuring Lipoprotein(a) in clinical practice: assay challenges, standardization, and interpretation**
Sang-Guk Lee (Yonsei University, Republic of Korea)
- 14:45-15:15 **Panel Discussion**
Jaehyun Bae (Hallym University, Republic of Korea)
Heung Yong Jin (Jeonbuk National University, Republic of Korea)
Jung-Kyu Han (Seoul National University, Republic of Korea)



Symposium 16

Sep 11 (Fri) 13:45-15:15 | Room 3 (3F, Conrad Seoul)

Evolution of High-Risk Coronary Plaques: From Detection to Prevention

CHAIRPERSONS : Byung Jin Kim (Sungkyunkwan University, Republic of Korea)
Jung Rae Cho (Hallym University, Republic of Korea)



- 13:45-14:03 **Evolution of vulnerable plaques: from natural history to preventive intervention**
Jinho Lee (Kyung Hee University, Republic of Korea)
- 14:03-14:21 **High-risk plaque features on CCTA: identification and clinical implications**
Sang Yoon Lee (Sungkyunkwan University, Republic of Korea)
- 14:21-14:39 **Intravascular imaging of vulnerable plaques: insights from IVUS and OCT**
Ju Hyeon Kim (University of Ulsan, Republic of Korea)
- 14:39-14:57 **Coronary physiology and plaque vulnerability: integrative relationship and prognostic implications**
Seokhun Yang (Seoul National University, Republic of Korea)
- 14:57-15:15 **Panel Discussion**
Bom Lee (CHA University, Republic of Korea)
Hyun Sung Joh (Seoul National University, Republic of Korea)
Hyung Joon Joo (Korea University, Republic of Korea)



Symposium 17

Sep 11 (Fri) 13:45-15:15 | Room 4 (5F, Conrad Seoul)

Metabolic Dysfunction, Fatty Liver, and Atherosclerosis

CHAIRPERSONS : Seok-Min Kang (Yonsei University, Republic of Korea)
Ki Chul Sung (Sungkyunkwan University, Republic of Korea)



- 13:45-14:05 **Fatty liver and residual cardiovascular risk: epidemiology and clinical implications**
Eun-Jung Rhee (Sungkyunkwan University, Republic of Korea)
- 14:05-14:25 **From lipotoxicity to atherosclerosis: MASLD/MetALD subtypes and cardiovascular risk - A hepatologist's perspective**
Su Jong Yu (Seoul National University, Republic of Korea)
- 14:25-14:45 **Therapeutic strategies for cardiometabolic risk reduction in MASLD**
Toru Miyoshi (Okayama University, Japan)
- 14:45-15:15 **Panel Discussion**
Bo Kyung Koo (Seoul National University, Republic of Korea)
Kyung-Jin Kim (Ewha Womans University, Republic of Korea)
Heesun Lee (Seoul National University, Republic of Korea)



Plenary Lecture 2

Sep 11 (Fri) 15:20-16:00 | Room 1,2,3 (3F, Conrad Seoul)



CHAIRPERSON : Woo Je Lee (University of Ulsan, Republic of Korea)

15:20-16:00 **Closing the gap between guidelines and reality in dyslipidemia management**

Michal Vrablik (Charles University, Czech Republic)



Symposium 18

Sep 11 (Fri) 16:10-17:40 | Room 1 (3F, Conrad Seoul)

Intensive LDL-C Lowering in Primary Prevention



CHAIRPERSONS : Eung Gyu Kim (Inje University, Republic of Korea)
Sang-Hyun Lim (The Catholic University of Korea, Republic of Korea)

16:10-16:30 **PCSK9 inhibition in primary prevention: insights from VESALIUS-CV and clinical implications**

Doo Sun Sim (Chonnam National University, Republic of Korea)

16:30-16:50 **Low LDL-C and brain safety: risk of hemorrhagic stroke and cognitive dysfunction**

Kwang-Yeol Park (Chung-Ang University, Republic of Korea)

16:50-17:10 **Early combination therapy in primary prevention**

Hoyoun Won (Chung-Ang University, Republic of Korea)

17:10-17:40 **Panel Discussion**

Hyung-Min Kwon (Seoul National University, Republic of Korea)

Minjeong Kim (Ewha Womans University, Republic of Korea)

Garam Jo (Hannam University, Republic of Korea)



Symposium 19

Sep 11 (Fri) 16:10-17:40 | Room 2 (3F, Conrad Seoul)

Next-generation Lipid-lowering Therapies: CETP, APOC3, and ANGPTL3 Inhibition (New Drugs 2)

CHAIRPERSONS : Sang Yup Lim (Korea University, Republic of Korea)
Soon Jun Hong (Korea University, Republic of Korea)



- 16:10-16:30 **CETP inhibition revisited: obicetrapib for LDL-C reduction and ASCVD risk management**
Mariko Harada-Shiba (Osaka Medical and Pharmaceutical University, Japan)
- 16:30-16:50 **APOC3 inhibition: targeting triglyceride-rich lipoproteins and residual risk**
Jin Wi (Gachon University, Republic of Korea)
- 16:50-17:10 **ANGPTL3 inhibition: expanding therapeutic opportunities beyond LDL-C**
Hye Moon Chung (Kyung Hee University, Republic of Korea)
- 17:10-17:40 **Panel Discussion**
Byung Sik Kim (Hanyang University, Republic of Korea)
Eun-Jung Rhee (Sungkyunkwan University, Republic of Korea)
Janghoon Lee (Kyungpook National University, Republic of Korea)



Symposium 20

Sep 11 (Fri) 16:10-17:40 | Room 3 (3F, Conrad Seoul)

Residual Cardiovascular Risk: Beyond LDL to Inflammation and Novel Targets

CHAIRPERSONS : Seung Woo Park (Sungkyunkwan University, Republic of Korea)
Young-Hoon Jeong (Chung-Ang University, Republic of Korea)



- 16:10-16:30 **Defining residual cardiovascular risk in the post-LDL era: unmet needs and mechanisms**
Hyung Joon Joo (Korea University, Republic of Korea)
- 16:30-16:50 **Targeting residual risk: Lp(a), triglyceride-rich lipoproteins, and inflammation**
Sung Gyun Ahn (Yonsei University, Republic of Korea)
- 16:50-17:10 **Beyond less is more: navigating residual thrombotic and inflammatory risk in AF and stable CAD**
Satoshi Yasuda (Tohoku University, Japan)
- 17:10-17:40 **Panel Discussion**
Jaehyun Bae (Hallym University, Republic of Korea)
Jung Myung Lee (Sahmyook Medical Center, Republic of Korea)
Jong Han Choi (Konkuk University, Republic of Korea)



Symposium 21 - KSSO-KSoLA Joint Symposium

Sep 11 (Fri) 16:10-17:40 | Room 4 (5F, Conrad Seoul)

Atherogenic Obesity: Beyond BMI to Lipid Dysfunction

CHAIRPERSONS : Min Sun Kim (University of Ulsan, Republic of Korea)
In-Kyung Jeong (Kyung Hee University, Republic of Korea)



16:10-16:30 **Lipid remodeling in adipose tissue and liver: a hidden link between obesity and atherosclerosis**

Yun-Hee Lee (Seoul National University, Republic of Korea)

16:30-16:50 **Remnant cholesterol and residual cardiovascular risk in obesity**

Young-Sang Lyu (Chosun University, Republic of Korea)

16:50-17:10 **Dual targeting of lipid and weight: emerging therapies and clinical strategies**

Chang Hee Jung (University of Ulsan, Republic of Korea)

17:10-17:40 **Panel Discussion**

Song-Yi Kim (Jeju National University, Republic of Korea)

Jee Hee Yoo (Chung-Ang University, Republic of Korea)

Heung Yong Jin (Jeonbuk National University, Republic of Korea)



Breakfast Symposium 5

Sep 12 (Sat) 07:50-08:20 | Room 1 (3F, Conrad Seoul)

Viartis

CHAIRPERSON : Myung Ho Jeong (Gwangju Veterans Hospital, Republic of Korea)

07:50-08:10 **Statin therapy strategies for newly diagnosed dyslipidemia patients in clinical practice**

Michal Vrablik (Charles University, Czech Republic)



Breakfast Symposium 6

Sep 12 (Sat) 07:50-08:20 | Room 2 (3F, Conrad Seoul)

Chong Kun Dang, GC Biopharma

CHAIRPERSONS : Kwang-Won Kim (Gachon University, Republic of Korea)
Kwang Kon Koh (Gachon University, Republic of Korea)

07:50-08:05 **Low-dose atorvastatin: addressing an unmet clinical need**

Sehoon Park (Seoul National University, Republic of Korea)

08:05-08:20 **The role of low-dose fenofibrate in the management of dyslipidemia**

Jaeseok Kim (Yonsei University, Republic of Korea)



Breakfast Symposium 7

Sep 12 (Sat) 07:50-08:20 | Room 3 (3F, Conrad Seoul)

Daiichi-Sankyo

CHAIRPERSON : Sang-Wook Lim (Cha University, Republic of Korea)

07:50-08:10 **A new oral LDL-C lowering agent with proven CV benefit: bempedoic acid**

Chang Hee Jung (University of Ulsan, Republic of Korea)





Breakfast Symposium 8

Sep 12(Sat) 07:50-08:26 | Room 4 (5F, Conrad Seoul)

Organon, GSK, Novartis

CHAIRPERSONS : Shung Chull Chae (Kyungpook National University, Republic of Korea)
Soon Jun Hong (Korea University, Republic of Korea)



07:50-08:02 **Integrated lipid management across the CKM spectrum: from evidence to practice**

Jong-Chan Youn (The Catholic University of Korea, Republic of Korea)

08:02-08:14 **Making vaccination routine for patients with cardiovascular disease**

Timothy C. Tan (Western Sydney University, Australia)

08:14-08:26 **Why is LDL-C control still insufficient? finding the breakthrough with leqvio cases in the aLLT era**

Jung-Joon Cha (Korea University, Republic of Korea)

TSLA-KSoLA Joint Symposium

Sep 12(Sat) 08:50-10:20 | Room 2 (3F, Conrad Seoul)

Contemporary Management of Residual Cardiovascular Risk in Asia

CHAIRPERSONS : Sang-Hyun Kim (Seoul National University, Republic of Korea)
Chin-Chou Huang (Taipei Veterans General Hospital, Taiwan)



08:50-09:10 **The emerging role of ApoB and triglyceride-rich lipoproteins**

Sin Yung Woo (Konyang University, Republic of Korea)

09:10-09:30 **Beyond LDL-C: targeting inflammation and lipoprotein(a) to address residual cardiovascular risk in Asia**

Ping-Yen Liu (National Cheng Kung University, Taiwan)

09:30-09:50 **Cardiometabolic residual risk in Asia: diabetes, metabolic dysfunction, and vascular aging**

Minkwan Kim (Yonsei University, Republic of Korea)

09:50-10:20 **Panel Discussion**

Young-Sang Lyu (Chosun University, Republic of Korea)

Hong Seok Lim (Ajou University, Republic of Korea)

Hansaem Jung (Jeong Hansaem Internal Medicine Clinic, Republic of Korea)



Symposium 22

Sep 12(Sat) 08:50-10:20 | Room 3 (3F, Conrad Seoul)

Lp(a) beyond the Known: From Metabolic Pathways to Clinical Translation

CHAIRPERSONS : Donghoon Choi (Yonsei University, Republic of Korea)
Keeho Song (Konkuk University, Republic of Korea)



- 08:50-09:10 **Oxidized phospholipids on lipoprotein(a): a key driver of atherothrombosis?**
Sotirios Tsimikas (University of California, San Diego, USA)
- 09:10-09:30 **Does lipoprotein(a) promote thrombosis? evidence from genetics and population studies**
Borge G. Nordestgaard (University of Copenhagen, Denmark)
- 09:30-09:50 **Epidemiology and cardiovascular events of Lp(a): what have we learned?**
Sang-Rok Lee (Jeonbuk National University, Republic of Korea)
- 09:50-10:20 **Panel Discussion**
Eu Jeong Ku (Seoul National University, Republic of Korea)
Young Sup Byun (Inje University, Republic of Korea)
Janghoon Lee (Kyungpook National University, Republic of Korea)



MSA-KSoLA Joint Symposium

Sep 12(Sat) 08:50-10:20 | Room 4 (5F, Conrad Seoul)

From Diversity to Action: Ethnicity, Genetics, and Closing the Treatment Gap in Asian Dyslipidemia

CHAIRPERSONS : Sang Ho Jo (Hallym University, Republic of Korea)
Hack-Lyoung Kim (Seoul National University, Republic of Korea)



- 08:50-09:10 **Dyslipidemia across ethnicities in Malaysia: who is at risk, and who is being left behind?**
Nor Ashikin Md Sari (University of Malaya, Malaysia)
- 09:10-09:30 **Genetic architecture of dyslipidemia and cardiovascular risk in East Asians: from monogenic variants to polygenic risk**
Soo Heon Kwak (Seoul National University, Republic of Korea)
- 09:30-09:50 **Epidemiological trends of dyslipidemia in Korea and their implications for Asian populations**
Hokyoo Lee (Yonsei University, Republic of Korea)
- 09:50-10:20 **Panel Discussion**
Ji Hyun Kim (The Catholic University of Korea, Republic of Korea)
Joon Ho Moon (Seoul National University, Republic of Korea)
Junghwan Park (Hanyang University, Republic of Korea)



Plenary Lecture 3

Sep 12(Sat) 10:40-11:20 | Room 1,2,3 (3F, Conrad Seoul)



CHAIRPERSON : Sang-Hyun Kim (Seoul National University, Republic of Korea)

10:40-11:20 **Beyond LDL-C lowering: strategies for maximizing residual ASCVD risk reduction**
Nathan D. Wong (University of California, Irvine, USA)

Plenary Lecture 4

Sep 12(Sat) 11:20-12:00 | Room 1,2,3 (3F, Conrad Seoul)



CHAIRPERSON : Ick Mo Chung (Ewha Womans University, Republic of Korea)

11:20-12:00 **Perspective on residual risk, inflammation, and atherosclerosis: from epidemiology to precision prevention**
Borge G. Nordestgaard (University of Copenhagen, Denmark)

Luncheon Symposium 6

Sep 12(Sat) 12:00-12:30 | Room 1 (3F, Conrad Seoul)

GSK



CHAIRPERSON : Sang Hong Baek (The Catholic University of Korea, Republic of Korea)

12:00-12:20 **Embedding shingles vaccination into everyday cardiology practice**
Timothy C. Tan (Western Sydney University, Australia)

Luncheon Symposium 7

Sep 12(Sat) 12:00-12:30 | Room 2 (3F, Conrad Seoul)

Hanmi Pharmaceutical



CHAIRPERSON : Hong Seog Seo (Korea University, Republic of Korea)

12:00-12:15 **New paradigm of initial therapy for hypertension: which patients benefit from amoprel?**
Young-Sang Lyu (Chosun University, Republic of Korea)

12:15-12:30 **Combination treatment in hypertension: why is losartan-based therapy effective?**
Hoyoun Won (Chung-Ang University, Republic of Korea)

Luncheon Symposium 8

Sep 12(Sat) 12:00-12:30 | Room 3 (3F, Conrad Seoul)

JW Pharmaceutical



CHAIRPERSON : Hak Chul Jang (Seoul National University, Republic of Korea)

12:00-12:15 **Cutting-edge care of pitavastatin with ezetimibe combination therapy**
Yeoree Yang (The Catholic University of Korea, Republic of Korea)

12:15-12:30 **Beyond LDL-C reduction comprehensive lipid control in DM patients**
Jun Hwa Hong (Eulji University, Republic of Korea)



Symposium 23 - KSH-KSoLA Joint Symposium

Sep 12(Sat) 13:00-14:00 | Room 1 (3F, Conrad Seoul)

**Hypertension, Lipids, and Vascular Aging:
Integrated Cardiovascular Risk Management**



CHAIRPERSONS : Kwang-il Kim (Seoul National University, Republic of Korea)
Jun Hwa Hong (Eulji University, Republic of Korea)

- 13:00-13:15 **Residual cardiovascular risk in hypertension despite optimal blood pressure control**
Hye Mee Kim (Chung-Ang University, Republic of Korea)
- 13:15-13:30 **Lipid management in hypertensive patients**
Jaehoon Chung (Gachon University, Republic of Korea)
- 13:30-13:45 **Obesity, insulin resistance, and hypertension-related vascular injury**
Mihye Seo (Soonchunhyang University, Republic of Korea)
- 13:45-14:00 **Panel Discussion**
Eu Jeong Ku (Seoul National University, Republic of Korea)
Hyo-Suk Ahn (The Catholic University of Korea, Republic of Korea)
Han-Mo Yang (Seoul National University, Republic of Korea)

Symposium 24 - KSCVI-KSoLA Joint Symposium

Sep 12(Sat) 13:00-14:00 | Room 2 (3F, Conrad Seoul)

Beyond Stenting: Contemporary Management of Residual Coronary Risk



CHAIRPERSONS : Joon Hyung Doh (Inje University, Republic of Korea)
Sang Yeub Lee (Chung-Ang University, Republic of Korea)

- 13:00-13:15 **Impact of lipid-lowering therapy on plaque stabilization and regression**
Jong Young Lee (Hallym University, Republic of Korea)
- 13:15-13:30 **Coronary microvascular dysfunction after PCI**
Hyun Sung Joh (Seoul National University, Republic of Korea)
- 13:30-13:45 **Discordance between CAC and coronary stenosis**
Sanghoon Shin (Ewha Womans University, Republic of Korea)
- 13:45-14:00 **Panel Discussion**
Yong Hyun Park (Pusan National University, Republic of Korea)
Hyun-Woong Park (Chungnam National University, Republic of Korea)
Jong Shin Woo (Kyung Hee University, Republic of Korea)
Soo Young Lee (Chung-Ang University, Republic of Korea)



Symposium 25 - KDA-KSoLA Joint Symposium

Sep 12(Sat) 13:00-14:00 | Room 3 (3F, Conrad Seoul)

Integrated Cardiometabolic Risk Management in Diabetes

CHAIRPERSONS : Sung Rae Kim (The Catholic University of Korea, Republic of Korea)
Hyuk-Sang Kwon (The Catholic University of Korea, Republic of Korea)



- 13:00-13:15 **Hypertriglyceridemia and remnant cholesterol in diabetes**
Sung Hee Choi (Seoul National University, Republic of Korea)
- 13:15-13:30 **Arterial stiffness and vascular aging in diabetes**
Hack-Lyoung Kim (Seoul National University, Republic of Korea)
- 13:30-13:45 **Coronary artery calcium and subclinical atherosclerosis in diabetes**
Janghoon Lee (Kyungpook National University, Republic of Korea)
- 13:45-14:00 **Panel Discussion**
Joon Ho Moon (Seoul National University, Republic of Korea)
Ki-Hyun Jeon (Seoul National University, Republic of Korea)
A Ram Hong (Chonnam National University, Republic of Korea)



Special Lecture 2

Sep 12(Sat) 13:20-13:50 | Room 4 (5F, Conrad Seoul)

CHAIRPERSON : Seong Hoon Choi (Hallym University, Republic of Korea)



- 13:20-13:50 **Atherosclerosis and atherosclerotic cardiovascular disease in Asia: the knowledge gap for the determinants**
Dong Zhao (Capital Medical University, China)



Symposium 26

Sep 12(Sat) 14:10-15:40 | Room 1 (3F, Conrad Seoul)

Integrated Cardiovascular-kidney-metabolic Care: A Multidisciplinary Approach to CKM Syndrome

CHAIRPERSONS : Yong-Jae Kim (Kim's Neurology Clinic, Republic of Korea)
Sung Kee Ryu (Ewha Womans University, Republic of Korea)



- 14:10-14:30 **Cardiologist perspective: implementing novel cardiometabolic therapies in CVD**
Donna Shu-Han Lin (Shin Kong Wu Ho-Su Memorial Hospital, Taiwan)
- 14:30-14:50 **Nephrologist's perspective: kidney protection strategies to improve cardio-kidney outcomes**
Jong Hyun Jhee (Yonsei University, Republic of Korea)
- 14:50-15:10 **Endocrinologist perspective: optimizing combination therapy in complex CKM patients**
Jae-Seung Yun (The Catholic University of Korea, Republic of Korea)
- 15:10-15:40 **Panel Discussion**
Jaeseok Kim (Yonsei University, Republic of Korea)
Min Kyung Lee (Hanyang University, Republic of Korea)
Min-Ho Lee (Sahmyook Medical Center, Republic of Korea)

Symposium 27

Sep 12(Sat) 14:10-15:40 | Room 2 (3F, Conrad Seoul)

AI-driven Innovations in Atherosclerosis

CHAIRPERSONS : Yongseek Park (Kyung Hee University, Republic of Korea)
Hyun Jae Kang (Seoul National University, Republic of Korea)



- 14:10-14:28 **AI-CVD: opportunistic testing of coronary calcium and beyond**
Nathan D. Wong (University of California, Irvine, USA)
- 14:28-14:46 **A+4DCT: angio enhanced dynamic CT for non-invasive functional diagnosis of coronary artery disease**
Joon Sang Lee (Yonsei University, Republic of Korea)
- 14:46-15:04 **Application of AI to coronary angiography**
Si-Hyuck Kang (Seoul National University, Republic of Korea)
- 15:04-15:22 **AI-based retinomics: cardiovascular risk prediction using retinal imaging**
Sahil Thakur (Medical Affairs, Mediwhale Inc., Singapore)
- 15:22-15:40 **Panel Discussion**
Kyu-Yong Ko (Inje University, Republic of Korea)
Hee-Dong Kim (Soonchunhyang University, Republic of Korea)
Kwan Yong Lee (The Catholic University of Korea, Republic of Korea)



Symposium 28

Sep 12(Sat) 14:10-15:40 | Room 3 (3F, Conrad Seoul)

Primary Prevention in Cardiovascular Disease: Beyond Traditional Risk Factors

CHAIRPERSONS : Bon-kwon Koo (Seoul National University, Republic of Korea)
Eun-Jung Rhee (Sungkyunkwan University, Republic of Korea)



14:10-14:30 **Lipid management in primary prevention: who, when, and how aggressive?**

Yeoree Yang (The Catholic University of Korea, Republic of Korea)

14:30-14:50 **Every minute counts: exercise snacks for better health and life's essential 8**

SoJung Lee (Kyung Hee University, Republic of Korea)

14:50-15:10 **Advancing cardiovascular management through vaccination**

Jae Hyoung Park (Korea University, Republic of Korea)

15:10-15:40 **Panel Discussion**

Mihye Seo (Soonchunhyang University, Republic of Korea)

Hyun Ju You (Seoul National University, Republic of Korea)

Jun Hwa Hong (Eulji University, Republic of Korea)



Symposium 29 - KES-KSoLA Joint Symposium

Sep 12(Sat) 14:10-15:40 | Room 4 (5F, Conrad Seoul)

Lipid Metabolism Across Endocrine Disorders: From Mechanism to Clinical Practice

CHAIRPERSONS : Sung Hee Choi (Seoul National University, Republic of Korea)
Sun Wook Cho (Seoul National University, Republic of Korea)



14:10-14:30 **Diabetic dyslipidemia: targeting residual risk beyond LDL-C lowering**

Kyung-Soo Kim (CHA University, Republic of Korea)

14:30-14:50 **Subclinical thyroid dysfunction: when should we treat for cardiovascular and metabolic health?**

Eu Jeong Ku (Seoul National University, Republic of Korea)

14:50-15:10 **Atherogenic dyslipidemia in women: PCOS, menopause, and cardiovascular risk**

Jeong Rang Park (Gyeongsang National University, Republic of Korea)

15:10-15:40 **Panel Discussion**

Dae-Young Kim (Inha University, Republic of Korea)

Seo Young Sohn (Inje University, Republic of Korea)

You-Bin Lee (Sungkyunkwan University, Republic of Korea)



Symposium 30

Sep 12(Sat) 15:40-17:10 | Room 1 (3F, Conrad Seoul)

Neural and Genetic Control of Eating Behavior and Cardiometabolic Health

CHAIRPERSONS : Yang Ha Kim (Ewha Womans University, Republic of Korea)
Min-Jeong Shin (Korea University, Republic of Korea)



- 15:40-16:00 **Dietary and social determinants of the human microbiome: implications for metabolic health**
Soyoung Kwak (Kyungpook National University, Republic of Korea)
- 16:00-16:20 **Understanding gene-diet interactions in cardiometabolic health: genetic risk scores and their modification by diet in Korean and UK biobank cohorts**
Sunmin Park (Hoseo University, Republic of Korea)
- 16:20-16:40 **Interaction effects of genetic variants and dietary intake on the development of metabolic syndrome**
Dayeon Shin (Ewha Womans University, Republic of Korea)
- 16:40-17:10 **Panel Discussion**
Mogan Gim (Hankuk University of Foreign Studies, Republic of Korea)
Jeong-Min Kim (Seoul National University, Republic of Korea)
Seung-Hwan Lee (The Catholic University of Korea, Republic of Korea)



EAS-KSoLA Joint Symposium

Sep 12(Sat) 15:40-17:10 | Room 2 (3F, Conrad Seoul)

Bridging Europe and Korea in Dyslipidemia Management: Guidelines, Gaps, and Future Directions

CHAIRPERSONS : Cheol-Young Park (Sungkyunkwan University, Republic of Korea)
Borge G. Nordestgaard (University of Copenhagen, Denmark)



- 15:40-16:00 **ESC/EAS dyslipidemia guidelines: recent updates and evidence base**
Meral Kayikcioglu (Ege University, Türkiye)
- 16:00-16:20 **Korean perspectives on dyslipidemia guidelines: recent update and challenges**
Jaehoon Chung (Gachon University, Republic of Korea)
- 16:20-16:40 **Translating guidelines into practice**
Wonjin Kim (CHA University, Republic of Korea)
- 16:40-17:10 **Panel Discussion**
Seon Mee Kang (Soonchunhyang University, Republic of Korea)
Min Kyung Lee (Hanyang University, Republic of Korea)
Ji Eun Lee (Korea University, Republic of Korea)



Symposium 31

Sep 12(Sat) 15:40-17:10 | Room 3 (3F, Conrad Seoul)

From Cells to Systems: Integrated Control of Cardiometabolic Health

CHAIRPERSONS : Goo Taeg Oh (Ewha Womans University, Republic of Korea)
Young Mi Park (Ewha Womans University, Republic of Korea)



- 15:40-16:00 **Non-inflammatory function of dendritic cell in the regulation of obesity-associated heart failure**
Kae Won Cho (Soonchunhyang University, Republic of Korea)
- 16:00-16:20 **Hepatic lipotoxicity and fibrotic remodeling in metabolic liver disease**
KyeongJin Kim (Inha University, Republic of Korea)
- 16:20-16:40 **From lipidomics to systems biology: decoding metabolic networks**
Guanghou Shui (Chinese Academy of Sciences, China)
- 16:40-17:10 **Panel Discussion**
Yoo-Wook Kwon (Seoul National University, Republic of Korea)
Hye Mee Kim (Chung-Ang University, Republic of Korea)
Kyung-Sun Heo (Chungnam National University, Republic of Korea)



Symposium 32

Sep 12(Sat) 15:40-17:10 | Room 4 (5F, Conrad Seoul)

Environmental Cardiovascular Risk

CHAIRPERSONS : Sun Ha Jee (Yonsei University, Republic of Korea)
Oh-Yoen Kim (Dong-A University, Republic of Korea)



- 15:40-16:00 **Air pollution and cardiovascular disease**
Sera Kim (Korea Environment Institute, Republic of Korea)
- 16:00-16:20 **Microplastics and cardiovascular health: current epidemiological evidence and challenges**
Dong-Wook Lee (Seoul National University, Republic of Korea)
- 16:20-16:40 **Climate change and cardiometabolic disease**
Whanhee Lee (Korea University, Republic of Korea)
- 16:40-17:10 **Panel Discussion**
Si-Hyuck Kang (Seoul National University, Republic of Korea)
Jong Young Lee (Hallym University, Republic of Korea)
Jun Young Hong (Yonsei University, Republic of Korea)



ORAL PRESENTATIONS

Oral Presentation 1

Sep 10(Thu) 14:30~16:00 | Room 1 (3F, Conrad Seoul)

CHAIRPERSONS : Hyun Kook (Chonnam National University, Republic of Korea)
Jong-Chan Youn (The Catholic University of Korea, Republic of Korea)



- OP1-1 **Improved survival and in vivo cholesterol-lowering efficacy of microencapsulated Lactobacillus plantarum LAB12**
Ismail M. Fareez (Universiti Teknologi MARA, Malaysia)
- OP1-2 **Lipid accumulation product and visceral adiposity indices as markers of hyperuricemia and gout: a meta-analysis of 575,000 patients**
Khalid Sarhan (Mansoura University Hospitals, Egypt)
- OP1-3 **Distinct vascular targets of metabolic and kidney dysfunction in adults without advanced**
Hyo-In Choi (Kangbuk Samsung Hospital, Republic of Korea)
- OP1-4 **A randomized, double-blind, placebo-controlled, crossover trial to comparatively evaluate the effects of magnesium hydride (MgH₂) on endothelial function: a pilot study**
Yasuhiro Endo (Niigata University of Pharmacy and Medical and Life Sciences, Japan)
- OP1-5 **Association of dietary sodium-to-potassium ratio with triglyceride-glucose index and metabolic syndrome risk in Korean adults: using data from the 2022-2023 Korea National Health and Nutrition Examination Survey**
Jisu Lee (Seoul Women's University, Republic of Korea)
- OP1-6 **A newly developed grain-based cereal product for glycemic spike management: effects on glycemic index, glycemic load, and postprandial glucose responses**
Soyeon Park (Graduate School of Dong-A University, Republic of Korea)
- OP1-7 **Nutraceutical modulation of the oral-vascular axis: emerging therapeutic strategies for periodontitis-associated atherosclerosis**
Viza Atiq Umar (Universitas Islam Sultan Agung, Indonesia)

Oral Presentation 2

Sep 11(Fri) 08:30~10:00 | Room 1 (3F, Conrad Seoul)

CHAIRPERSONS : Cheol-Ung Choi (Korea University, Republic of Korea)
Jung-Kyu Han (Seoul National University, Republic of Korea)



- OP2-1 **Renal lipidomic profiling reveals boerhaavia diffusa extract ameliorates saturated fatty acid lipotoxicity and mitochondrial decay independent of systemic adiposity**
Lee On Ying (The Hong Kong Polytechnic University, China)
- OP2-2 **Extrahepatic bile acid synthesis reprograms multiorgan cholesterol flux in cardiovascular disease**
Hosung Bae (University of Iowa, United States)
- OP2-3 **Prdx3 deficiency triggers cGAS-STING signaling pathway induced vascular smooth muscle cell senescence and phenotypic switching in abdominal aortic aneurysm**
Moajury Jung (Ewha Womans University, Republic of Korea)
- OP2-4 **Sphingosine-1-phosphate receptor 1 deletion in smooth muscle cells protects against atherosclerosis in apoE-deficient mice by reducing lipid droplet formation**
Inbar Habaz (Hamilton Health Sciences, Canada)
- OP2-5 **Senolytic therapy attenuates atherosclerosis and metabolic dysfunction by targeting cellular senescence in western diet-fed Ldlr KO mice**
Hye Rang Park (Korea Research Institute of Bioscience and Biotechnology (KRIBB), Republic of Korea)
- OP2-6 **The role of LGI3 in adipocytes and macrophages in atherosclerosis**
Do Hee Yu (Department of Life Sciences, Ewha Womans University, Republic of Korea)
- OP2-7 **Cyclic induction of OSKM expression mitigates atherosclerosis through vascular anti-inflammatory remodeling independent of systemic metabolic effects**
Young Hoon Seo (Korea Research Institute of Bioscience and Biotechnology (KRIBB), Republic of Korea)
- OP2-8 **Extracellular vesicles produced by M2-polarized macrophages drive atherosclerosis regression by reprogramming Ly-6Chi monocytes & enhancing efferocytosis**
Robert L. Raffai (University of California, San Francisco, United States)



Oral Presentation 3

Sep 12(Sat) 08:50~10:20 | Room 1 (3F, Conrad)

CHAIRPERSONS : Hyeong Kyu Park (Soonchunhyang University, Republic of Korea),
Han-Mo Yang (Seoul National University, Republic of Korea)



- OP3-1 **Residual risk of remnant cholesterol in patients treated to LDL-C goal: a landmark analysis of the RACING trial**
Sungyeon Park (Yonsei University Wonju College of Medicine, Republic of Korea)
- OP3-2 **Lower cardiovascular event risk with bempedoic acid versus ezetimibe in statin-intolerant atherosclerotic cardiovascular disease (ASCVD): a 3,540-patient TriNetX analysis**
Ahmed Elaraby (Faculty of medicine, Al-Azhar University, Egypt)
- OP3-3 **Age-dependent association of atherogenic dyslipidemia with incident cardiovascular disease: a nationwide Korean cohort study**
Ye Seul Yang (Seoul National University College of Medicine, Republic of Korea)
- OP3-4 **Deep learning analysis of BMI, metabolic risk factors, and sex hormones in U.S. women: a NHANES study**
Saheed Oladele Amusat (Beaumont Hospital, Ireland)
- OP3-5 **Prevalence of high inflammatory risk in atherosclerotic cardiovascular disease with and without chronic kidney disease: findings from POSEIDON - a global cross-sectional prevalence study**
Hong-Ki Jeon (Yonsei University, Republic of Korea)
- OP3-6 **Real-world efficacy and tolerability of inclisiran in Malaysian patients with atherosclerotic cardiovascular disease: a single-centre experience**
Kim Fong Ng (KPJ Kluang Specialist Hospital, Malaysia)
- OP3-7 **A Korean multidimensional social determinants of health index identifies individuals at elevated risk of severe coronary artery calcification: evidence from the CMERC cohort**
Jooeun Jeon (Ewha Womans University Mokdong Hospital, Republic of Korea)
- OP3-8 **Efficacy and safety of enlicitide decanoate, an oral macrocyclic peptide inhibitor of PCSK9, compared with bempedoic acid, ezetimibe, or bempedoic acid co-administered with ezetimibe in statin-treated adults with hypercholesterolemia: phase 3 CORALreef AddOn trial**
Maria Carolina Emilia Villanueva (MSD Philippines, Republic of Korea)

MODERATED POSTER PRESENTATIONS

Moderated Poster Presentation 1

Sep 11(Fri) 12:45-13:45 | Studio 5 (6F, Conrad Seoul)

MODERATOR : Jun Namkung (Yonsei University, Republic of Korea)



- MPP1-1 **Comparative lipid profiling of celastrol-treated atherosclerotic ApoE^{-/-} mice on a high-fat diet**
Nurin Yasmin Mohd Khairudin (Universiti Teknologi MARA, Malaysia)
- MPP1-2 **MMP11 promotes endothelial senescence and atherosclerosis through proteolytic cleavage of FLRT2**
Hyun Jung Hwang (College of Medicine, Inha University, Republic of Korea)
- MPP1-3 **LGI3 as a novel therapeutic target in atherosclerosis: regulation of macrophage inflammation and plaque progression**
Jing Jin (Ewha Womans University, Republic of Korea)
- MPP1-4 **Involvement of vimentin in oxLDL-induced microparticle release from macrophages**
Soonhyeong Oh (College of Medicine, Ewha Womans University, Republic of Korea)
- MPP1-5 **Aging rewires the vascular-wall regulatory landscape to redirect diet-induced atherosclerosis**
Ju Young Kim (Kyungpook National University Hospital, Republic of Korea)
- MPP1-6 **A novel cyclodextrin derivative modulates macrophage lipid accumulation and inflammatory responses relevant to atherosclerosis**
Soobin Chang (Hanyang University, Republic of Korea)



Moderated Poster Presentation 2

Sep 11 (Fri) 12:45-13:45 | Studio 6 (6F, Conrad Seoul)

MODERATOR : Jaehoon Chung (Gachon University, Republic of Korea)



- MPP2-1 **Deciphering the differential impact of ART classes on vascular morphology and lipid profiles in HIV-positive patients with coronary artery disease**
Nuriat Efendieva (Pirogov Russian National Research Medical University, Russia)
- MPP2-2 **Autophagy-based restoration of glucosylceramide catabolism in Gaucher disease**
Minji Kim (Ewha Womans University, Republic of Korea)
- MPP2-3 **Loss of PCSK9 enhances ANP expression to attenuate post-MI cardiac inflammation**
Na Hyeon Yoon (Ewha Womans University, Republic of Korea)
- MPP2-4 **BMI-mediated inflammatory pathways and miR-92a-3p dysregulation: novel insights into cardiovascular risk stratification**
Fitri Bin Kahar (Universiti Putra Malaysia, Malaysia)
- MPP2-5 **Whole-body 18F-FDG PET demonstrates coordinated splenic and arterial inflammatory activation in acute ischemic stroke**
Sue Young Ha (Seoul National University Hospital, Seoul National University College of Medicine, Republic of Korea)
- MPP2-6 **Revealing the hidden signals: prognostic impact of pericoronary fat attenuation index (FAI) in major adverse cardiovascular events (MACE) and coronary plaque instability - a systematic review and meta-analysis**
Muhamad Fajri Addai (National Cardiovascular Center Harapan Kita - Faculty of Medicine, Universitas Indonesia, Indonesia)
- MPP2-7 **Circulating PD-L1+CD10- immature neutrophils and integrated immunometabolic signatures associated with diabetic kidney disease severity in type 2 diabetes**
Junseo Kim (Chungnam National University Hospital & College of Medicine, Republic of Korea)



Moderated Poster Presentation 3

Sep 11 (Fri) 12:45-13:45 | Studio 7 (6F, Conrad Seoul)

MODERATOR : Mi-Hyang Jung (The Catholic University of Korea, Republic of Korea)



- MPP3-1 **Comparative cardiovascular risk in monogenic familial hypercholesterolemia versus polygenic hypercholesterolemia: a meta-analysis of long-term cohorts**
Moaz Abouelmagd (Kasr Alainy Faculty of Medicine, Cairo University, Egypt)
- MPP3-2 **Lysosomal acid lipase deficiency misdiagnosed as familial hypercholesterolaemia: a family case series with a novel homozygous LIPA variant and dramatic response to enzyme replacement therapy**
Koukab AL Farsi (Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Oman)
- MPP3-3 **Effect of roxadustat on lipid profile in adults with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials**
Ammar Yasser Ali (Faculty of Medicine, Mansoura University, Egypt)
- MPP3-4 **Real-world hsCRP awareness and clinical practice patterns in ASCVD, CKD, and heart failure: South Korea findings from the FLARE (Focus on Levels of Awareness and perceptions REgarding hs-CRP in identifying SI in ASCVD, CKD and HF management) study**
Kyungsoo Won (Novo Nordisk Korea, Republic of Korea)
- MPP3-5 **Does early PCSK9 inhibition improve outcomes after acute ischemic stroke? a systematic review and meta-analysis**
Amir Hegazi (Mansoura University, Egypt)
- MPP3-6 **Effect of alirocumab/evolocumab on lipid levels and MACEs after PCI for ACS: a meta-analysis of 3474 patients**
Khalid Sarhan (Mansoura University Hospital, Egypt)
- MPP3-7 **Clinical impact of imaging-guided percutaneous coronary intervention in heavily calcified coronary lesions: a systematic review and meta-analysis of randomized controlled trials**
Ahmed Adel (Faculty of Medicine, Zagazig University, Egypt)
- MPP3-8 **Triglyceride-to-HDL-cholesterol ratio as a marker of adiposity in young Korean adults: a single-center cross-sectional study**
Sehyun Kim (Seoul National University College of Medicine, Republic of Korea)



Moderated Poster Presentation 4

Sep 12(Sat) 13:00-14:00 | Studio 5 (6F, Conrad Seoul)

MODERATOR : Su Myung Jung (Sungkyunkwan University, Republic of Korea)



- MPP4-1 **Unravelling the divergent pathological and transcriptional profile of lipotoxic renal tubular injury and lipoprotein glomerulopathy in APOE-deficient and humanised hAPOE4 knock-in mice**
Martin Ho Yin Yeung (The Hong Kong Polytechnic University, China)
- MPP4-2 **Regulation of cholesterol and bile acid homeostasis by ceramide chain length**
Eunji Noh (Ewha Womans University, Republic of Korea)
- MPP4-3 **Docosahexaenoic acid attenuates vascular calcification with regulation of miR-29b1**
Hyeonji Lee (Yonsei University, Republic of Korea)
- MPP4-4 **Lipid droplet sequestration protects vascular smooth muscle cells from saturated fatty acid-induced NFκB activation**
Laura Alonso-Herranz (Aarhus University, Denmark)
- MPP4-5 **CIAPIN1 orchestrates vascular phenotypic switching as a redox-sensitive repressor of Tp53**
Seongpyo Lee (Chungbuk National University, Republic of Korea)
- MPP4-6 **Endothelial CAP1 acts as a gatekeeper of vascular homeostasis via the formation of an adenylyl cyclase and caveolin-1 complex**
You Ji Kim (Seoul National University Hospital, Republic of Korea)



Moderated Poster Presentation 5

Sep 12(Sat) 13:00-14:00 | Studio 6 (6F, Conrad Seoul)

MODERATOR : Jeong-Min Kim (Seoul National University, Republic of Korea)



- MPP5-1 **Association of a body shape index and the 5-year incidence of dyslipidemia and hypertension among Filipinos in the LIFECARE cohort**
Bayani Pocholo T. Maglinte (University of the Philippines - Philippine General Hospital, Philippines)
- MPP5-2 **Burden of ischemic stroke attributable to high LDL cholesterol and high body mass index in adults aged 55+years: a comparative analysis of mortality, DALYs, and YLDs by sex across socio-demographic index levels**
Zavia Putri Salsabila (Islamic Weleri Hospital, Indonesia)
- MPP5-3 **Association between triglyceride-to-HDL cholesterol ratio and coronary artery spasm: differential effect according to diabetes mellitus status**
You Jin Lee (Korea University Guro Hospital, Republic of Korea)
- MPP5-4 **Decoupling atherosclerosis from vasospasm: insights from the ApoB/ApoA1 ratio**
Abiseka Panji Baskoro (Korea University Guro Hospital, Republic of Korea)
- MPP5-5 **Carbohydrate-fat dietary patterns modify protein-cardiometabolic association: a cross-sectional study in Singaporean adults**
Weili Hu (National University of Singapore, Singapore)
- MPP5-6 **Dietary macronutrient intake modifies the association between cognitive function and cardiovascular disease risk: a cross-sectional study in Singapore adults**
Shuqi Li (National University of Singapore, Singapore)
- MPP5-7 **Distribution of diet-attributable ischemic heart disease mortality across Indonesian provinces: an ecological analysis**
Zulfania Rahmah (Al Aziz Hospital, Indonesia)



Moderated Poster Presentation 6

Sep 12(Sat) 13:00-14:00 | Studio 7 (6F, Conrad Seoul)

MODERATOR : Jae-Han Jeon (Kyungpook National University, Republic of Korea)



- MPP6-1 Association of obesity status and LDL-cholesterol levels with all-cause mortality in statin users aged 75 years and older: a nationwide population-based cohort study
Mihye Seo (Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Republic of Korea)
- MPP6-2 Wharton's jelly-derived mesenchymal stem cells for limb salvage in diabetes-associated chronic limb-threatening ischemia: a systematic review and meta-analysis
Ghazy Wira Pradipta (Sebelas Maret University, Indonesia)
- MPP6-3 Atherogenic index of plasma in metabolic syndrome: a systematic review and meta-analysis
Ahmed Almezaine (Tanta University Hospital, Egypt)
- MPP6-4 Diagnostic accuracy of artificial intelligence for image-based unstable carotid plaque identification: a systematic review and meta-analysis
Youssef Soliman (Assiut University, Egypt)
- MPP6-5 Regional variation in the clinical impact of intravascular imaging for left main coronary atherosclerotic disease
Hendrianus (Natuna General Hospital, Indonesia)
- MPP6-6 Effectiveness and safety of pravastatin in postmenopausal women with dyslipidemia in Korea: results from the MELODY study
Jun Hwa Hong (Daejeon Eulji Medical Center, Republic of Korea)

GENERAL POSTER DISPLAY

Scan the QR
E-Posters



- PE01 Synthetic HDL-based therapy for selective modulation of cholesterol efflux in atheroma macrophages
Khalfa Benadouda (University of Helsinki, Finland)
- PE02 Hepatic LPLAT10 overexpression alters lipoprotein cholesterol distribution in diabetic mice
Kahori Shimizu (Graduate School of Pharmaceutical Sciences, The University of Osaka, Japan)
- PE03 ANGPTL4 attenuates multicellular atherogenic remodeling: validation in a human iPSC-derived atheroid model
Dong Im Cho (Chonnam National University Hospital, Republic of Korea)
- PE04 Boerhaavia diffusa ameliorates renal dyslipidaemia by enhancing fatty acid oxidation in high-fat diet-induced chronic kidney disease mouse models
Ching In Chung (The Hong Kong Polytechnic University, Hong Kong, China)
- PE05 Ret finger protein deficiency attenuates adipogenesis in mice with high fat diet-induced obesity
Yun-Gyeong Lee (Chonnam National University Medical School, Republic of Korea)
- PE06 Fermented pear extract ameliorates free fatty acid-induced hepatic steatosis in HepG2 cells
Van-Long Truong (Kyungpook University, Republic of Korea)
- PE07 Nicotinamide promotes lipophagy and cholesterol efflux through SIRT1-LXRα deacetylation-ABCA1 axis in vascular smooth muscle cells
Poo-Reum Choi (College of Medicine, Yeungnam University, Republic of Korea)
- PE08 APOA1 potentiates the protective effects of platelet-derived extracellular vesicles on lymphatic function during atherosclerosis
Élizabeth Lacroix (Montreal Heart Institute, Canada)
- PE09 Clinical significance of PAI-1 and lipid metabolism disturbances in patients with ischemic heart disease
Kadirova Nargiza (Tashkent State Medical University, Uzbekistan)
- PE10 Post-stroke changes associated with glucocorticoid dysregulation
Huiju Jo (Ewha Womans University, Republic of Korea)



- PE11 Effects of a self-care model on the prevention of kidney complications in patients with type 2 diabetes: a quasi-experimental study
Natthavirot Choodum (Faculty of Nursing, Songkhla Rajabhat University, Thailand)
- PE12 Impact of high-sensitivity C-reactive protein cutoff selection on cardiovascular risk classification beyond lipid measurements in Korean adults: a KNHANES 2024 study
Rihwa Choi (GC Labs, Republic of Korea)
- PE14 Integrative post-GWAS analyses identify HEIDI-clean causal genes for hypertension in East Asian populations
Yongho Jee (Ewha Womans University Seoul Hospital, Republic of Korea)
- PE15 Trends in lipid-lowering drug prescription patterns in patients with dyslipidemia: a real-world data from 2010 to 2023
Seung-Hyun Ko (The Catholic University of Korea, Republic of Korea)
- PE16 Sex differences of lipoprotein (a) levels and cardiovascular risk: retrospective multicenter cohort study of Korean patients
Subin Lim (Ewha Womans University Seoul Hospital, Republic of Korea)
- PE17 Provincial variation in non-alcoholic fatty liver disease burden and associated risk factors among adults aged 50-69 years in Indonesia: a population-based study
Nazala Safira (Banjarnegara Muhammadiyah Hospital, Indonesia)
- PE18 Baseline atherogenic dyslipidemia and early NT-proBNP clearance in acute heart failure: a retrospective cohort study
Muhammad Ayyub Aiman bin Mohd Fauzi (Universiti Teknologi MARA, Malaysia)
- PE19 Resolving the genetic dark matter of inherited dyslipidemia: structural variation and polygenic susceptibility identify 24.4% of previously unexplained cases
Muhammad Hamza Mubarak (Universitas Islam Indonesia, Indonesia)
- PE20 Lipid-lowering efficacy in omani patients with familial hypercholesterolemia
Suaad Al Mukhaini (University Medical City, Oman)
- PE21 Beyond weight loss: psychiatric and eating behavior safety signals associated with GLP-1 therapies in FAERS
Ekram Hassan Hasanin (University of Tripoli, Libya)
- PE22 Hepatic insulin resistance index and associated metabolic profiles in Korean adults with type 2 diabetes mellitus
Paul Kim (Kyung Hee University, Republic of Korea)

- PE23 Cumulative burden of lipid-related indices as a predictor of incident type 2 diabetes in young adults: a nationwide cohort study
Jung Heo (Myongji Hospital, Hanyang University College of Medicine, Republic of Korea)
- PE24 Genetic spectrum of familial hypercholesterolaemia in multigenerational families in Oman
Mohsin Al-Lawati (Sultan Qaboos University, Oman)
- PE25 Higher diabetes-related distress predicts failure to achieve LDL-C targets and poor glycemic recovery in diabetes mellitus patients following myocardial infarction
Marcelino Adiska Megantara (Sebelas Maret University, Indonesia)
- PE26 From measurement to motivation: an integrated framework connecting 3D anthropometry, AI-driven phenotyping, and behavioral theory for precision obesity intervention
Minseo Kim (Sookmyung Women's University, Republic of Korea)
- PE27 Analysis of miRNAs expression in abdominal aortic aneurysm and their potential as biomarkers
Kenshi Yoshimura (Nakatsu Municipal Hospital, Japan)
- PE28 Admission NT-proBNP level as a marker of biological frailty and cause-specific mortality after percutaneous coronary intervention
Aditya Reza Pratama (Korea University Guro Hospital, Republic of Korea)
- PE29 High obstructive sleep apnea risk association with carotid atherosclerosis and impaired vitality in obese hypertensive patients with type 2 diabetes
Borys Shelest (Kharkiv National Medical University, Ukraine)
- PE30 Impact of statin use on net adverse clinical and cerebral events after ESUS
Kangho Choi (Chonnam National University Hospital, Republic of Korea)
- PE31 Blood pressure variability and cerebral autoregulation failure: accelerated cognitive decline in the NACC cohort
Moaz Abouelmagd (Kasr Alainy Faculty of medicine, Cairo University, Egypt)
- PE32 The preventive effect of routine dental scaling on acute myocardial infarction in patients with diabetes: a long-term follow-up study
Tsai-Wei Hsu (Taipei Medical University Hospital, Taiwan)
- PE33 Deficiency of p300/CBP-associated factor exacerbates cardiac remodeling by disrupting CAMKK2 acetylation
Anna Jeong (Chonnam National University Medical School, Republic of Korea)



EVENT INFORMATION

- PE34 Synergistic attenuation of adipose inflammation and hepatic steatosis by combined taurine and leucine supplementation in a diet-induced model of sarcopenic obesity
Amara Zulfiqar (Changwon National University, Republic of Korea)
- PE35 Can the 4-year cholesterol screening gap be compensated? A machine learning imputation simulation for high-risk classification
ChanSeok Son (Korea University Graduate School, Republic of Korea)
- PE36 Distinct cardiometabolic and pulmonary profiles across obesity-metabolic health phenotypes
Dabin Lee (Graduate School of Dong-A University, Republic of Korea)
- PE37 Peripheral microcurrent stimulation promotes neuroprotection and remyelination in a rat model of hypoxia-ischemia
Dong Rak Kwon (Catholic University of Daegu School of Medicine, Republic of Korea)

Welcome Kit

Every registered participant will receive an exclusive ICoLA 2026 welcome kit!



Automatic Folding UV Umbrella

&



Eco Bag

* Available while supplies last.

Photogenic Event

Gather your colleagues and capture your ICoLA moments together. After the congress, special prizes will be awarded to the three group photos with the largest number of participants.



Domestic Participants:
Starbucks E-Gift Card



Overseas Participants:
Amazon E-Card

Lucky Draw Event

Join our Lucky Draw during the Breakfast Symposia and Closing Ceremony for a chance to win exciting prizes!


Breakfast Symposia (Day 2~3)

Room 1~3(3F) & Room 4(5F)

- Breakfast Symposium 1~4: 07:30-08:00, September 11(Fri), 2026
- Breakfast Symposium 5~8: 07:50-08:20, September 12(Sat), 2026



Galaxy Buds
(1 Winner per Room)




Starbucks Gift Card KRW 30,000
(2 Winners per Room)

Closing Ceremony (Day 3)


17:10, September 12(Sat), 2026 / Room 1,2,3 (3F)




LG gram
(1 Winner)



Dyson Airwrap
(1 Winner)



iPad mini
(1 Winner)



Starbucks Gift Card KRW 50,000
(5 Winners)

Stamp Tour Event

Collect stamps from at least 80% of the participating exhibition booths and submit your Stamp Tour sheet to the Stamp Tour Event Desk (5F) for verification. Rewards will be sent after the congress.



Domestic Participants:
Starbucks E-Gift Card (KRW 20,000)



Overseas Participants:
Amazon E-Card (USD 20)

Congress Review Event

Share your memorable ICoLA 2026 experience with photos and a short review in an MS Word file, and submit it to the Secretariat at lipid@planbear.co.kr. Outstanding submissions will receive special prizes after the congress.



Domestic Participants:
Department Store E-Gift Card



Overseas Participants:
Amazon E-Card

Domestic
Participants
Only

Social Media Like & Share Event

SNS 공유 이벤트

ICoLA 2026 SNS 계정을 팔로우하시고, SNS 게시물에 '좋아요'를 클릭 & 공유해주세요!
좋아요 및 공유 횟수가 가장 많은 분을 추첨하여 행사 종료 후 스타벅스 커피 쿠폰을 보내드립니다!

Domestic
Participants
Only

Thursday Attendance Event

목요일 세션에 3시간 참여하고,
스타벅스 1만원권 GET!

국내 참가자를 대상으로 9월 10일(목) 13:00부터 3시간 이상 체류하신 분께
행사 종료 후 스타벅스 E-기프트카드(1만원권)를 증정합니다!

※ 체류 시간은 명찰 QR 태그 기록을 기준으로 확인하오니,
반드시 입실 시 1회, 퇴실 시 1회의 QR 태그를 부탁드립니다.

연사의 발표를 실시간 번역으로 청취해보세요!

Experience the presentation with live translation in your native language!

별도의 앱 설치 없이, 오른쪽에 있는 QR코드를 통해 접속하실 수 있습니다.

No separate app installation is required. You can access the live translation service via the QR code provided on the right.

네트워크 오류 또는 접속 이상이 발생할 경우, 페이지를 새로고침(🔄)하여 주십시오.

If you experience a network error or difficulty accessing the service, please refresh(🔄) the web page.



ICoLA 2026 실시간 통역 바로가기

ICoLA 2026 Join the Live Translation

통역 서비스 입장 QR
Live Translation Page QR



통역 서비스 제공 강의장: Room 2
Available Live Translation Service Room: Room 2

*본 서비스는 Room 2에서 9월 10일(목)-12일(토) 3일 간 제공됩니다.

*This service will be available for 3 days,
from September 10(Thu) to 12(Sat) in Room 2.



CME CREDITS (FOR KOREAN PARTICIPANTS)

구분		9/10(목)	9/11(금)	9/12(토)
의사	대한의사협회 연수교육 평점	최대 3평점	최대 6평점	최대 6평점
영양사	임상영양사 전문연수교육 (CPD)	5평점 * 3일 모두 수강하셔도 최대 5평점 승인됩니다.		

- 등록 시 의사 면허번호를 정확하게 입력해주시기 바랍니다. 면허번호 오류 시 의사협회 평점이 수자에서 누락될 수 있습니다.
- 학술회 종료 후, 학회 사무국에서 의사 명단을 의사협회 연수교육 시스템에 등록하게 되면 자동으로 평점이 부여되고 있으며 개인에게 평점카드를 발급하지 않습니다. (소요기간: 약 4주)
- 대한의사협회 2016년도 연수교육 관리 변경사항 공지에 따라 학술회 참석 증명을 위한 출결 확인 작업이 있을 예정입니다.
- 대회 참석 시 명찰 내 QR코드를 2회 이상 QR코드 리더기에 태그하셔야 출결 확인이 되니 유의 바랍니다. (입실 시 1회, 퇴실 시 1회)

부분 평점 인정 기준

1시간 미만	0평점
1시간 이상 2시간 미만	1평점
2시간 이상 3시간 미만	2평점
3시간 이상 4시간 미만	3평점
4시간 이상 5시간 미만	4평점
5시간 이상 6시간 미만	5평점
6시간 이상	6평점 (1일 최대 이수 가능 평점: 최대 6평점)

QR코드 리더기 위치 안내



BOOTH EXHIBITION

Enjoy ICoLA Stamp Tour!

Join our stamp tour and get a chance to win a prize.



OR



Overseas Participants:
Amazon E-Card
(USD 20)

Domestic Participants:
Starbucks E-Gift Card
(KRW 20,000)

Visit, Collect and Get!

Visit exhibition booths and collect stamps from 80% of the total booths.

(Diamond, Platinum, Gold and JLA booth stamps are mandatory to collect.)
Please submit your completed stamp tour sheet to Stamp Tour Event Desk in Lobby, 5F. (Reward will be reimbursed after the congress.)

3F




- * Stamp tour event sheet will be distributed at registration desk.
- * Please collect your stamp on the given sheet, not on this program book.

D1	D2	P1	P2
Mandatory Hanmi Pharmaceutical	Mandatory JW Pharmaceutical	Mandatory ORGANON	Mandatory DAEWOOONG
P3	P4	G1	
Mandatory GSK	Mandatory NOVARTIS	Mandatory VIATRIS	



5F



6F



G2	G3	G4	S1	S2	S3
Mandatory YUHAN	Mandatory JEIL Pharm.	Mandatory DAIICHI SANKYO KOREA	AMGEN	CKD Pharm	DONG-A ST
S4	S5	S6	B1	B2	B3
GCPharma	HANLIM PHARM	inno.N	Alvogen	CELLTRION Pharm	YOOYOUNG
B4	B5	B6	B7	B8	B9
HYUNDAI PHARM	SK chemicals	sanofi	LG Chem	BORYUNG	Otsuka
B10	B11	B12	B13	1	2
daewon Pharmaceutical	novo nordisk	SAMJIN SAMJIN PHARM.	Ahngook pharm.	KOREA UNITED PHARM	BCWORLD PHARM
3	4	5	6	7	8
명문제약(주)	MENARINI	ILDONG 일동제약	Abbott	간일제약(주)	Boehringer Ingelheim
9	10	11	12	13	14
Lilly	DAEWOONG BIO INC.	IL-YANG PHARM.	Firson	SHIN POONG PHARM. CO. LTD.	DONGWHA PHARM
JLA					
Mandatory JLA					

SPONSORSHIP

DIAMOND

JW Pharmaceutical

Hanmi Pharmaceutical

PLATINUM

DAEWOONG **ORGANON** **NOVARTIS** **GSK**

GOLD

YUHAN **VIATRIS** **JEIL Pharm.** **DAIICHI SANKYO KOREA**

SILVER

AMGEN **CKD Pharm** **GCPharma** **inno.N** **HANLIM PHARM** **DONG-A ST**

BRONZE

LG Chem **sanofi** **CELLTRION Pharm** **daewon Pharmaceutical** **YOOYOUNG**
Ahngook pharm. **HYUNDAI PHARM** **BORYUNG** **novo nordisk** **SK chemicals**
SAMJIN SAMJIN PHARM. **Otsuka** **Alvogen**



ICoLA 2027

The 16th International Congress on
Lipid & Atherosclerosis



September
9 (Thu)-11 (Sat), 2027

Conrad Seoul, Republic of Korea



한국지질·동맥경화학회
The Korean Society of Lipid and Atherosclerosis




SoLA 2027

한국지질·동맥경화학회 춘계학술대회
2027 Spring Congress on
Lipid and Atherosclerosis of KSoLA

2027. 4. 2. (금)-3. (토)
경주 화백컨벤션센터 (HICO)



Submit to JLA! KSoLA's Official Journal



The JLA is an official journal of the Korean Society of Lipid and Atherosclerosis. The journal is devoted to the dissemination of knowledge of the mechanisms responsible for lipid metabolism and atherosclerosis and enhance insight into prevention, treatment, and ultimate cure for cardiovascular diseases. The JLA covers basic, translational, and clinical research of lipid and atherosclerosis. The JLA also encourages articles on broad aspects of vascular biology, thrombosis, metabolism, nutrition, or cardiovascular health. Only manuscripts written in English are accepted. This journal includes review article, editorial, original article, brief report, opinion, and letter to the editor.

Submit your manuscript



We invite you to submit your papers to JLA. The Journal is published on the official website of the JLA (<https://e-jla.org/>), and you can submit your work through the online submission system (<https://www.editorialmanager.com/la/>).

Recent articles






Check out our recently published articles.
<https://www.e-jla.org/index.php>

No submission fee



No author's submission fee or other publication-related fee since all article processing costs is supported by KSoLA.



Korean Guidelines for the Management of Dyslipidemia 2026

Committee of Clinical Practice Guideline of
the Korean Society of Lipid and Atherosclerosis



혈관건강지킴이 Lipid on YouTube
Like, Share, Subscribe!
www.youtube.com/@lipidorkr






MEMO

Atozet[®]

Better start early, start strong

Faster Choices,

Better Outcomes!^{1,2*}



* Images are for illustrative purposes only and may not represent the actual size of ATOZET[®]. For detailed information on the size, shape, and appearance of the product, please refer to the full prescribing information approved by the MFDS.

[Study design] This prospective, randomized, double-blind, placebo-controlled, balanced-parallel group trial was conducted to test the primary hypothesis that the coadministration of ezetimibe with atorvastatin would result in a significantly greater reduction in LDL-C than atorvastatin alone. 628 patients (aged 18 years) with baseline LDL-C 145 to 250 mg/dL and triglycerides 350 mg/dL were randomly assigned to receive 1 of the following for 12 weeks: ezetimibe (10 mg/d, n=65); atorvastatin (10, 20, 40, or 80 mg/d, n=248); ezetimibe (10 mg) plus atorvastatin (10, 20, 40, or 80 mg/d, n=255); or placebo (n=60). The primary efficacy end point was the percentage reduction in direct LDL-C from baseline to final assessment for the intent-to-treat population.

¹ ATOZET[®] is available in four strengths: 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg.

[Primary endpoint result] Mean change in direct LDL-C from baseline: Ezetimibe/Atorvastatin overall vs. Atorvastatin overall = -54.5% vs. -42.4% (P<0.01).²

LDL-C, low-density lipoprotein cholesterol; **MFDS**, Ministry of Food and Drug Safety.

References 1. MFDS. ATOZET[®] Product information. 2. Ballantyne CM, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. *Circulation*. 2003;107(19):2409-2415.

[Importer / Marketing Authorization Holder / Distributor]

ORGANON 한국오가논

Organon Korea | 4F, 50 Jong-ro 1-gil, Jongno-gu, Seoul 03142, Korea
(Tel) 1577-8582 <https://www.organon.com/korea>

Copyright © 2026 Organon group of companies. All rights reserved.

[Distributor]

BORYUNG

136, Changgyeonggung-ro, Jongno-gu, Seoul, Korea (Wonnam-dong)
(Tel) 080-708-8088 <https://www.boryung.co.kr>



오늘 싱그릭스[#]

대상포진 이 환자의 여정에 걸림돌이 되지 않도록²

오늘 선생님께서 **직접, 접종 권유**를 시작해주세요.

#싱글릭스 효능 요약¹⁾
대상포진 (HZ; herpes zoster)의 예방
-만 50세 이상의 성인
-만 18세 이상에서 질병 혹은 치료로 인한 면역저하 또는 면역억제로 인하여
대상포진의 위험이 증가한 것을 것으로 예상되는 사람
(예. 자가조혈세포이식자, 고혈압, 혈액암, 고혈당기이식 환자)

소 국내 제품설명서, 2. Piazza MF, et al. Vaccines (Basel). 2020 Jan 10;8(1):20.

* 실제 약의 크기는 이미지와 다를 수 있습니다.

[illegible]

본 세팅 사항은 (주)글로벌시스템코리아의 법선 담당자에게 문의하여 주십시오.
 GSK 제품 사용 중 발생한 이상사건(제약번호는 000-000-0000 또는 koreasafetyreporting.co.kr으로 보고)에 주시기를 바랍니다. Trademarks are owned by or licensed to the GSK group of companies. ©2025 GSK group of companies or its licensee.

		
(주)글로벌시스템코리아 서울특별시 용산구 한강대로 62 Tel. 080-000-4100	광동 제약 경기도 과천시 과학로16가길52 (영등포)	GC녹십자 경기도 용인시 기흥구 이천로 300번 107 (의정부)



[Product Information]

처방하시기 전 QR 코드 또는 식품의약품안전처
의약품통합정보시스템 (<http://nedrug.mfds.go.kr>)을 통해
상세제품정보를 참조하시기 바랍니다.

PM-KR-SGX-JRNA-250005 Nov 2025

Daewoong Pharmaceutical's Ezetimibe/Statin Combination Portfolio for LDL-C Goal Attainment

With three Ezetimibe/Statin combination therapies⁶—Rosuvastatin/Ezetimibe (**CREZET**)¹², Pitavastatin/Ezetimibe (**BAROEZET**)³, and Atorvastatin/Ezetimibe (**LITORVAZET**)^{4,5}—Daewoong Pharmaceutical offers a broad range of treatment options for dyslipidemia management.



Ezetimibe/Rosuvastatin

CZ CREZET® Tab.

크레젯정[Ezetimibe / Rosuvastatin] 10/2.5, 10/5, 10/10, 10/20mg



Pitavastatin/Ezetimibe

Baroezet® Tab.

바로에젯정 Pitavastatin / Ezetimibe 1/10 mg



Ezetimibe/Atorvastatin

Litorvazet Tab 

리토바젯정 [Ezetimibe / Atorvastatin]
10/5, 10/10, 10/20, 10/40mg



Ref.: 1. Yang YJ, et al. *Clin Ther*. 2017;39(11):107-117. 2. Data on file. Regulatory Phase 3 clinical study [DW_DWT507301]. 3. Data on file. Regulatory Phase 3 clinical study [AD-228P3]. 4. Bays HE, et al. *AM J Cardiol*. 2013;112:1885-1895. 5. Leiter LA, et al. *Am J Cardiol*. 2008;102(11):1495-1501. 6. Prescribing information for individual products. Accessed Mar 13, 2026.

* This medicinal product has undergone strict quality control. If, at the time of purchase, the product is past its use-by date or expiration date, or is deteriorated, spoiled, contaminated, or damaged, it may be exchanged or refunded through the pharmacy or other pharmaceutical retailer from which it was purchased, in accordance with the Consumer Dispute Resolution Standards established by the Korea Fair Trade Commission. To report adverse reactions or apply for relief for drug-related injury, please contact the Korea Institute of Drug Safety & Risk Management (164-5223) / (14-3330) or the Daewoong Pharmaceutical Customer Service Center (toll-free) at 080-550-8308-9 (www.daewoong.co.kr). For detailed and up-to-date approved information, please refer to the Ministry of Food and Drug Safety's integrated drug information system (<https://indf.mfds.go.kr/>) or consult the product insert.

CREZET 10/5 **BAROEZET** 1/10 **LITORVAZET** 10/10



ICoLA 2026

The 15th International Congress on
Lipid & Atherosclerosis



ICoLA | by KSoLA
International Congress
on Lipid & Atherosclerosis



KSoLA
The Korean Society on Lipid and Atherosclerosis